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Abstract  
 
 Obesity and diabetes are major public health problems facing the world today. 
Extending our understanding of adipose tissue biology, and how it changes in obesity, 
will hopefully better equip our society in dealing with the obesity epidemic. Macrophages 
and other immune cells accumulate in the adipose tissue in obesity and secrete cytokines 
that can promote insulin resistance. Adipose tissue macrophages (ATMs) are thought to 
originate from bone marrow-derived monocytes, which infiltrate the tissue from the 
circulation. Much work has been done to demonstrate that inhibition of monocyte 
recruitment to the adipose tissue can ameliorate insulin resistance. While monocytes can 
enter the adipose tissue, we have shown here that local macrophage proliferation may be 
the predominant mechanism by which macrophages self-renew in the adipose tissue. 
 We demonstrated that two cell proliferation markers, Ki67 and EdU, can be readily 
detected in macrophages isolated from adipose tissue of both lean and obese mice. These 
analyses revealed that 2-4% of ATMs in lean and 10-20% of ATMs in obese mice 
express the proliferation marker Ki67. Importantly, Ki67+ macrophages were identified 
within the adipose tissue in crown-like structures. Similarly, a 3-hour in vivo pulse with 
the thymidine analog EdU showed that nearly 5% of macrophages in epididymal adipose 
tissue of ob/ob mice were in the S-phase of cell division. Interestingly, obesity increased 
the rate of macrophage proliferation in adipose tissue but did not affect macrophage 
proliferation in other tissues. We also used clodronate liposomes to deplete circulating 
monocytes in obese mice. Surprisingly, monocyte depletion for a total of at least 80 hours 
did not cause a decrease in ATM content in adipose tissue. Prolonged exposure of mice to 
 v 
EdU in drinking water revealed that approximately half of the ATMs in the epididymal 
fat pads of ob/ob mice had proliferated locally within 80 hours. Amazingly, these rates 
were the same with or without monocyte depletion, meaning that the proliferating cells 
were not freshly recruited monocytes. 
Overall, these results suggest that local proliferation unexpectedly makes a major 
contribution to maintaining the large population of macrophages present in the obese 
adipose tissue in the steady state. This suggests that increased rates of local macrophage 
proliferation may also be partly responsible for the massive increase in ATM content that 
occurs in obesity. This information could have implications for future therapeutic 
strategies in the management of diabetes. 
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In order to survive, animals must be able to store excess energy in times of plenty, 
and release that energy when food sources are absent. The most volume- and weight–
efficient way to store excess energy is in the form of lipid1. Lipid is an ideal form in 
which to store energy due to its high energy density and a hydrophobic nature that 
reduces obligatory water retention, allowing animals to store as much energy in as little 
weight as possible. In most animals lipids are stored in distinct adipose depots2. Over the 
course of evolutionary history the adipose tissue has developed into an organ that is 
efficient at the uptake of excess nutrient, the conversion of that nutrient into lipid 
triglyceride, and the controlled release of lipid during starvation conditions2,3. For 
example, adult polar bears must endure seasonal fasting for four or more months each 
year and lose up to 40% of their total body weight in that time. Depending on the amount 
of fat stored, nearly all of that weight loss can be due to fat catabolism, while most or all 
lean body mass is retained4. Thus, the adipose tissue has the capacity to undergo 
enormous changes in mass in response to environmental conditions, and its proper 
function is critical for survival.  
  In humans, adipose tissue is also very efficient at storing excess nutrient and has 
the capacity to expand tremendously – often to a stage where greater than 50% of the 
total body weight is adipose tissue5. In the time of our ancestors, this ability to store 
excess energy was beneficial for survival during times of scarcity, but in the modern 
civilized world, human exposure to excess nutrient is perpetual. As a result, the global 
rates of overweight and obesity have reached epidemic levels. Obesity is typically 
defined as a body mass index (BMI) of over 30 kg/m2 – a calculation based on a person’s 
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height and weight. According to the World Health Organization more than 1 in 10 of the 
world’s adult population was obese in 2008, and its prevalence is on the rise. Overweight 
and obesity were the fifth leading cause of global deaths6. Obesity is associated with 
many additional health problems, including insulin resistance, cardiovascular disease, 
fatty liver disease, and cancer, among several others7,8. Indeed, 44% of the global diabetes 
burden, 23% of ischemic heart disease, and a large portion of cancer are attributable to 
obesity6. In the United States, annual health care expenditures related to overweight and 
obesity are projected to reach nearly $1 trillion by 2030, which represents nearly 20% of 
total spending on health care6,9. In order for our society to deal with this worsening 
epidemic, we must advance our understanding of adipose tissue physiology and the 
pathogenesis of diabetes and obesity. 
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Mechanisms of Insulin Resistance 
 
Adipocyte Dysfunction and Inflammation 
Obesity and insulin resistance are closely associated with a state of chronic, low-
grade inflammation3,10-12. Adipose tissue plays a central role in the development of insulin 
resistance. While muscle and liver are the main insulin-sensitive tissues of the body13, 
adipose tissue is also highly insulin sensitive and is able to exert profound control over 
the function of those peripheral tissues14. Interestingly, the inflammatory response that 
occurs in obesity seems to originate in and remain within the adipose tissue itself14. 
Adipose tissue expansion places tremendous strain on the cells within the tissue, 
ultimately leading to adipocyte dysfunction, in which adipocytes are unable to synthesize 
triglyceride and instead release free fatty acid into the circulation14. Under these 
conditions, both the hypertrophic adipocytes and resident adipose tissue macrophages 
produce inflammatory cytokines that act to interfere with insulin signaling in adipocytes 
and other cells, as well as to recruit additional immune cells to the adipose tissue, which 
produce more cytokines in a cycle of inflammation15. These and other topics will be 
discussed below.  
 
The Lipid Spillover Hypothesis 
One prevailing theory on how obesity leads to insulin resistance is the 
“lipotoxicity” theory first proposed in 199516. In the early stages of obesity, adipocytes 
remain capable of storing the increasing load of incoming triglyceride. As adipose tissue 
expands further, the ability of the adipocytes to store lipid decreases and excess lipid 
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spills over into the circulation in a phenomenon known as lipolysis. This increased rate of 
lipolysis in obesity results in increased plasma levels of free fatty acids (FFAs)16,17. In 
obesity, FFAs and lipid metabolites can accumulate in liver and muscle, and cause insulin 
resistance in these tissues14,18. Several lines of evidence support this view. Obesity and 
insulin resistance are strongly associated with high circulating FFA levels18. Reductions 
of FFA levels using anti-lipolytic compounds or by enhancement of adipose tissue 
activity has been shown to improve insulin sensitivity in peripheral tissues19,20. However, 
it is clear that insulin resistance can occur in the absence of elevated FFA levels, and that 
elevated FFA levels do not always cause insulin resistance21. Nonetheless, there is no 
doubt that elevated FFA and lipid metabolites in liver and muscle can cause insulin 
resistance in those tissues, as shown in humans using lipid infusions and in mice using 
tissue-specific lipoprotein lipase overexpression22-24. The importance of the ability of the 
adipose tissue to sequester lipids away from the rest of the body is highlighted by the 
hyperlipidemia and insulin resistance observed in lipodystrophic mice25,26 and humans27,28 
that lack adipose tissue. Lipid sequestration and release represent important ways in 
which adipose tissue function can affect insulin sensitivity throughout the rest of the 
body.  
 
Adipose Tissue Hypoxia 
Another consequence of adipose tissue growth is increased oxygen demand. 
Adipose tissue growth is dependent on new blood vessel formation29. However, in 
obesity, the closely coupled processes of adipocyte expansion and neovascularization are 
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disrupted, and adipose tissue hypo-perfusion and hypoxia result30. Improvement of 
adipose tissue perfusion by overexpression of vascular endothelial growth factor (VEGF) 
specifically in adipose tissue was shown to improve hypoxia, adipose tissue inflammation 
and whole body glucose homeostasis31. Overexpression of VEGF in adipose tissue has 
also been shown to reduce adiposity32. A recent study has confirmed that adipose tissue 
vasculature depletion causes systemic insulin resistance and local adipose tissue 
inflammation, while overexpression of VEGF decreased adipose tissue inflammation and 
reduced systemic insulin resistance in a high fat diet (HFD)-fed mouse model33. These 
studies again highlight the important role adipose tissue plays in the proper metabolic 
functioning of the entire body. Adipose tissue hypo-perfusion may be a precipitating 
factor in the series of events leading to adipocyte dysfunction, adipose tissue 
inflammation, and total body insulin resistance.  
 
Endoplasmic Reticulum Stress 
As adipose tissue expands, tremendous strain is placed on the adipocytes to 
accommodate the influx of nutrient, and to process and store that nutrient as triglyceride. 
The surge in protein and lipid synthesis increases the synthetic demands placed on the 
endoplasmic reticulum (ER). When protein production exceeds the capacity of the ER to 
properly fold and modify nascent peptides, a cellular response takes place that slows 
protein production and increases the expression of protein folding chaperones34. It has 
been shown that cellular changes that occur in ER stress can inhibit insulin signaling in 
adipocytes in mice35,36 and the ER stress response has been shown to be elevated in the 
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adipose tissue of humans with insulin resistance37. Genetic manipulation of the ER stress 
pathway can alleviate insulin resistance in mouse models of obesity36, and treatment of 
obese mice with small molecules that aid in protein folding also improve glucose 
homeostasis38. It should be noted that ER stress can also contribute to insulin resistance in 
peripheral tissues as well39,40. ER stress can also initiate inflammatory signaling within the 
adipocyte36,41, and may provide a link between excessive adipose tissue growth and the 
emergence of adipose tissue inflammation. 
 
The progression of insulin resistance to diabetes mellitus 
In the early phases of obesity and in the pre-diabetic state, the insulin resistance of 
peripheral tissues does not immediately result in hyperglycemia42. During this time, the 
pancreatic beta cells are able to maintan normal blood glucose levels despite insulin 
resistance of the peripheral tissues by increasing their mass, in a process known as beta 
cell compensation42. Beta cell mass is increased in obese non-diabetic compared to lean 
non-diabetic humans43 and the same is true in rodents44. During this time, the beta cells 
also increase their expression of insulin45. This phase of compensatory hyperinsulinemia 
is followed by a decline in beta cell function42. If obesity progresses and insulin resistance 
worsens, tremendous strain in placed on the beta cells, and the ability of the beta cells to 
produce the compensatory hyperinsulinemia decreases46,47. Beta cell mass declines, and it 
has been shown that beta cells undergo apoptosis43. The details and mechanisms of beta 
cell failure in diabetes, which include lipotoxicity from adipose tissue lipid spillover as 
well as ER stress, are reviewed in Prentki and Nolan, 200642. As the beta cells 
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progressively fail, the declining insulin levels are no longer able to overcome the insulin 
resistance of the peripheral tissues, and hyperglycemia ensues48. Clinically, a fasting 
plasma glucose level below 100 mg/dl is considered normal, 101-125 mg/dl is considered 
“impaired fasting glucose” or pre-diabetic, and diabetes mellitus is diagnosed when a 
patient has a fasting plasma glucose of over 126 mg/dl49,50. 
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Obesity and Inflammation 
 
Discovery of Inflammation in Obesity 
 Perhaps the most important factor in causing and driving adipose tissue dysfunction 
is inflammation. Whether induced by ER stress, hypoxia, or other factors, adipose tissue 
hypertrophy often results in adipocyte dysfunction. Adipocyte dysfunction, in turn, is a 
critical component in a cycle of inflammation within the adipose tissue14. Hotamisligil 
and colleagues and Feinstein and colleagues first discovered in 1993 that the 
inflammatory cytokine tumor necrosis factor alpha (TNFα) was expressed in adipose 
tissue and was capable of inducing systemic insulin resistance10,51. Importantly, TNFα 
expression was shown to be greatly increased in obese animals compared to lean controls. 
Since that time, the adipose tissue has been identified as the source of many cytokines 
and some even consider adipose tissue an endocrine organ52.  
 
Inflammation and Insulin Resistance 
 Since 1993, hundreds of studies have confirmed the link between inflammation and 
insulin resistance, and numerous excellent reviews on the subject exist3,12,14,15, but key 
points will be discussed here. Studies in humans revealed that obese adipose tissue 
expresses TNFα constitutively, and that its expression in adipose tissue decreases after 
weight loss53,54. Similarly, TNFα concentrations were found to be elevated in the plasma 
of obese patients, and TNFα plasma levels decreased after weight loss55. Expression of 
the inflammatory cytokine interleukin 1 beta (IL-1β) and its receptor are increased in the 
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visceral adipose tissue of obese humans56 and IL-1 and TNF have been shown to act 
synergistically and can increase one another’s production57. Further evidence for obesity 
being an inflammatory condition came from several studies that confirmed that elevated 
inflammatory markers in obese patients are predictive of the development of type 2 
diabetes58-62. Other inflammatory cytokines increased in obesity include interferon 
gamma, resistin, and interleukin 6 (IL-6) among many others (reviewed in Shoelson et al. 
200612). Importantly, TNFα infusion into healthy human subjects can quickly cause 
insulin resistance63 and IL-1β has been shown to induce insulin resistance in cultured 
adipocytes64.  Taken together, these and many other findings support the concept that 
obesity is an inflammatory condition, and inflammation itself is linked to the 
development of insulin resistance in humans.  
 Importantly, attenuation of inflammation leads to an improvement in insulin 
resistance. Neutralization of TNFα using a TNF receptor-IgG-fusion protein in a 
genetically obese rat model caused significant improvement in peripheral glucose 
uptake10. Also genetic deletion of TNFα in obese mouse models resulted in improved 
insulin sensitivity65. Unfortunately early studies which attempted to neutralize TNFα in 
human patients did not show a benefit in insulin sensitivity66. However, neutralization of 
TNFα has shown improvements in insulin resistance in patients with rheumatoid arthritis 
and ankylosing spondylitis67,68. Also, treatment with Interleukin-1-receptor antagonist 
yielded a mild improved glycaemia in human patients with type 2 diabetes69 and also in 
mice70,71. These studies indicate that inflammatory cytokines play a critical role in the 
regulation of insulin sensitivity. 
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Inflammatory Signals Interfere With Insulin Signaling 
 Inflammatory cytokines interfere with the insulin signaling pathway within insulin 
target cells3,12,14. Adipocytes and other insulin target cells express the insulin receptor at 
their surface. The insulin receptor, when activated by insulin, phosphorylates the insulin 
receptor substrate (IRS) proteins within the cell on specific tyrosine residues. (For an 
excellent review on insulin signaling, see Taniguchi, 200672). These IRS proteins are 
responsible for conveying the insulin signal to downstream effectors in the cell that 
produce the cellular response to insulin. Inflammatory signals interfere with the insulin 
signaling pathway at the level of the IRS proteins3,12,14.  
 The stress-activated protein kinases c-Jun amino-terminal kinase (JNK) and 
inhibitor of nuclear factor kappa B (NFκB) kinase subunit beta (IKKβ) have proven to be 
critical molecules that link inflammation and insulin signaling12,73. Many inflammatory 
signals, both from extracellular and intracellular sources, produce cellular responses 
involving these molecules. For example, JNK and IKKβ are both activated by 
inflammatory cytokine signaling from outside the cell and ER stress signals from within 
the cell3,12. TNFα signaling was first shown to inhibit insulin signaling through inhibitory 
serine phosphorylation of IRS-1 in 199674. Since that time it has become clear that TNFα 
and IL-1β signals activate JNK75,76 and JNK, in turn, directly inhibits the insulin signaling 
cascade by inhibiting IRS-1 activity77. JNK accomplishes this by phosphorylating IRS-1 
at Serine 307 which prevents it from being activated by the insulin receptor77,78. Indeed 
JNK has been shown to play a central role in the development of obesity and insulin 
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resistance in liver, muscle, adipose tissue79, and more recently in macrophages as well 80, 
and genetic JNK deficiency protects mice from insulin resistance79. Similarly, 
inflammatory cytokines, including TNFα and IL-1β, also activate IKKβ75,76. Pro-
inflammatory IKKβ activity has also been shown to increase in obesity, and inhibition of 
IKKβ activity, particularly in macrophages, has been shown to protect mice from the 
insulin resistance in obesity81-83. Unlike JNK however, IKKβ activity inhibits insulin 
signaling not through direct action on IRS-1, but by activating the transcription of a long 
list of inflammatory genes84,85, which subsequently feed back on the cell and inhibit the 
response to insulin. This is an important way in which inflammatory signaling 
perpetuates a cycle of inflammation and insulin resistance.  
 
Inflammatory Signals Also Inhibit Adipocyte Lipogenic Function 
 Inflammation also plays a role in generating the adipose tissue dysfunction and 
“lipid spillover” discussed above. In obesity, adipocytes are less able to sequester lipid 
and store it as triglyceride14. This may be partly due to the fact that enzymes responsible 
for de novo synthesis of fatty acids and the esterification of fatty acids intro triglyceride 
are significantly reduced in the adipose tissue of obese humans86 as well as in obese 
mouse models87,88. The master regulator of these adipogenic genes, and a necessary factor 
in the maintenance of mature adipocyte function, is peroxisome proliferator-activated 
receptor-gamma (PPARγ)89,90. Several studies have shown that TNFα and IL-1 are able to 
downregulate PPARγ action in adipocytes91-94. Thus, inflammatory cytokines not only 
inhibit insulin signaling in adipocytes, they also may contribute to the inhibition of 
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adipocyte function and the resultant increase in lipid release from adipocytes in the obese 
state. 
 
Immune Cells in Adipose Tissue 
 Numerous immune cell types populate the adipose tissue, and the quantities and 
proportions of those cell types change in obesity, contributing to inflammatory cytokine 
production. Macrophages are the largest population of immune cell type in the adipose 
tissue and produce the majority of the inflammatory cytokines that are increased in 
obesity11, and will be discussed extensively below. Another large population of immune 
cells in adipose tissue is eosinophils, which are very numerous in lean adipose tissue, and 
decrease their presence in obesity95. Eosinophils have been shown to secrete interleukin 4 
(IL-4) in the adipose tissue, which modulates macrophage function and adipose tissue 
insulin sensitivity in a beneficial way95. Similarly, regulatory T cell number in lean 
adipose tissue is very high, and decreases in obesity96. Concurrent with the decrease in 
regulatory T cells, an increase in CD4 TH1 cells and CD8 T cells occurs in the adipose 
tissue in obesity97,98. Importantly, the influx of these T cells has been shown to precede 
macrophage accumulation in the adipose tissue, and depletion of CD8 T cells decreases 
macrophage content in obese adipose tissue, suggesting that T cells play a role in 
controlling adipose tissue macrophage content97. The various subsets of natural killer T 
cells also appear to be involved in adipose tissue inflammation and metabolism, although 
there are conflicting reports as to what that role may be99-103. B cells have also been 
shown to increase in their presence in adipose tissue in obesity and produce pathogenic 
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antibodies in the adipose tissue98. Interestingly, mast cells, which are normally associated 
with allergic responses, increase in the adipose tissue in obesity, and deficiency or 
stabilization of mast cells has been shown to improve insulin sensitivity in obese mice104. 
Thus, the adipose tissue is host to a variety of immune cells whose populations change 
with obesity and immune cell recruitment contributes to adipose tissue inflammation and 
obesity.  
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Adipose Tissue Macrophages 
 
Macrophages Accumulate in Adipose Tissue in Obesity 
 Analysis of gene expression in cells isolated from obese adipose tissue has revealed 
that adipose tissue macrophages (ATMs) are the predominant source of the inflammatory 
cytokines elevated in obesity11. Macrophages accumulate in the adipose tissue in huge 
numbers in the obese state, a phenomenon first described by Weisberg et. al. and Xu et. 
al. in 200311,105. In a lean individual, of all non-adipocyte cell types in the adipose tissue 
(called the stromal-vascular fraction, or SVF) only 5-10% may consist of macrophages, 
while macrophages can be as high as 40% of all stromal cells in obese human adipose 
tissue, and as high as 50% in morbidly obese mouse adipose tissue11. Importantly, ATM 
content is closely correlated with adipocyte size and body weight in mice and in 
humans11,106-108. Furthermore, macrophage accumulation in adipose tissue is temporally 
associated with the onset of insulin resistance105. Also, it is very interesting to note that in 
humans, not all obese individuals have insulin resistance, and inflammatory gene 
expression and ATM content in visceral adipose tissue has been shown to be a far better 
predictor of insulin resistance than simple measures of adiposity109. Taken together, these 
studies provide good evidence that under physiological conditions, macrophage content 
within adipose tissue is increased in obesity and is linked to the development of insulin 
resistance. 
 
Alterations in Adipose Tissue Macrophage Content Affect Insulin Sensitivity 
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 Since the initial discovery of macrophages in adipose tissue, many attempts have 
been made to either decrease or increase ATM content, in an attempt to determine if 
doing so would alter insulin sensitivity. Several groups have succeeded in demonstrating 
improved insulin sensitivity associated with a decrease in ATM content. For example, 
treatment of obese mice with the insulin-sensitizing drug rosiglitazone has been shown to 
decrease ATM content105. Surgery-induced weight loss in morbidly obese human subjects 
has been shown to be associated with decreased macrophage content in white adipose 
tissue and decreased inflammatory gene expression110. Diet and exercise-induced weight 
loss has also been found to decrease ATM content111. Diptheria toxin-induced cell death 
of macrophages within the adipose tissue in obese mice was associated with improved 
insulin sensitivity as well112. Depletion of ATMs by intraperitoneal clodronate liposome 
injection also improved insulin sensitivity in obese mouse models113.   
 Inhibition of monocyte recruitment to the adipose tissue has, in certain cases, been 
found to produce a modest decrease in ATM content and was associated with improved 
insulin sensitivity in those cases108,114,115. This topic will be discussed in further detail 
below. Conversely, adipose tissue-specific overexpression of monocyte chemoattractant 
protein 1 (MCP-1) increased ATM content and decreased insulin sensitivity in both lean 
and obese mouse models115,116. Taken together, these studies support the concept that 
ATM content is closely correlated with insulin resistance. 
 
The Increased Inflammatory Properties of ATMs in Obesity.  
 Not only do macrophage numbers increase in adipose tissue in obesity, but their 
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activation state is also polarized towards a pro-inflammatory phenotype117,118. 
Macrophages are a very versatile cell type, able to attain a broad range of functional 
states based on the cues present in their environment119. In lean mice, ATMs are generally 
characterized by an anti-inflammatory “M2-like” phenotype, as determined by their 
surface marker and gene expression profiles117. Anti-inflammatory macrophages are 
characterized by anti-inflammatory cytokines rather than pro-inflammatory cytokines, 
and are thought to prevent inflammation and promote tissue repair120. Anti-inflammatory 
“M2-like” macrophages are believed to be generated by exposure to anti-inflammatory 
signals such as IL-4, IL-10, IL-13, and glucocorticoids, whereas pro-inflammatory “M1-
like” macrophage phenotype is believed to be a response to exposure to inflammatory 
cytokines such as interferon gamma and TNF-α120. In obesity, a significant fraction of 
ATMs lose that anti-inflammatory phenotype and become more pro-inflammatory, or 
“M1-like”, expressing inflammatory cytokines that inhibit the ability of the surrounding 
adipocytes to respond to insulin118. While macrophage sub-populations in the adipose 
tissue may have overlapping marker expression profiles, it is generally thought that 
CD11c expression is characteristic of pro-inflammatory macrophage subtypes112,118,121. 
Interestingly, preventing ATMs from attaining an anti-inflammatory phenotype in obese 
mouse adipose tissue predisposes mice to diet-induced obesity and insulin resistance122. 
Furthermore, a recent publication reported that systemic helminth infection, a canonical 
M2-polarizing condition, was associated with a shift in ATM phenotype in obese mice to 
an entirely anti-inflammatory state, and insulin sensitivity was normalized in these 
mice95. Taken together, these reports provide strong evidence that not only increased 
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macrophage number, but also the increased inflammatory ATM phenotype that occurs in 
obesity plays an important role in the development of insulin resistance. 
 
Inhibition of Adipose Tissue Macrophage Inflammation Improves Insulin Sensitivity 
 In addition to absolute decreases in macrophage number in adipose tissue, 
inhibition of inflammatory signaling within macrophages can also improve insulin 
resistance. Genetic deletion of JNK specifically in hematopoietic cells, accomplished by 
bone marrow transplant, was sufficient to protect mice from diet-induced insulin 
resistance even though the mice became just as obese as control mice123. This study was 
confirmed and extended by a recent publication showing deletion of both JNK1 and 
JNK2 specifically in macrophages protects mice from obesity-induced insulin 
resistance80. It is important to note that both of these studies also observed a decreased 
macrophage content in the adipose tissue in the JNK-deficient macrophage condition. 
Similarly to macrophage-specific JNK deletion, macrophage-specific IKKβ deletion also 
protects mice from diet-induced adipose tissue inflammation and insulin resistance 
without protecting from diet-induced weight gain83. While these studies emphasize the 
role of inflammatory signaling within macrophages in obesity, they have all been limited 
to studying macrophages throughout the body, while the question of the role of 
macrophages specifically within adipose tissue has been unresolved. Our group recently 
developed siRNA delivery technology able to specifically target macrophages within 
obese adipose tissue124. Using this technology, we were able to silence production of two 
inflammatory cytokines, TNFα and osteopontin, specifically in adipose tissue 
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macrophages, and show improved whole body glucose tolerance. This study confirms the 
role of inflammatory signaling specifically in macrophages, specifically in adipose tissue, 
as being of central importance in the development of insulin resistance in obesity. 
 
Adipose Tissue Macrophages May Also Play a Protective Role 
 Despite the extensive evidence that ATMs are inflammatory and act to exacerbate 
insulin resistance, there is also evidence for a protective role of macrophages. Kosteli et. 
al. have shown that acute fasting-induced lipolysis or drug-induced lipolysis is associated 
with rapid recruitment of macrophages to the adipose tissue125. Furthermore, they showed 
that depletion of macrophages was associated with increased lipid release from adipose 
tissue during fasting conditions. These findings were confirmed by another group that 
directly observed that ATMs accumulate lipid in obese mice and become triglyceride 
foam cells even in the basal obese state126. Additional evidence supporting this hypothesis 
is that macrophages in the obese adipose tissue localize around dead and dying 
adipocytes, forming structures termed crown-like structures (CLS)106,107. When examined 
by electron microscopy, the macrophages in these structures were found to contain lipid-
filled phagolysosomes, suggesting they sequester the lipid being released from the dying 
adipocytes and prevent it from entering the circulation106. These reports support a role for 
ATMs in taking up excess lipid in order to protect the rest of the body from the toxic 
effects of free fatty acids being released from adipocytes.  
  
20 
 
  
21 
The Origin of ATMs 
 
Evidence That ATMs Are Derived From Monocytes 
 Much effort has been focused on determining the factors that attract macrophages 
to the adipose tissue in obesity. It is generally believed that myeloid precursors develop 
in the bone marrow, enter the circulation as blood monocytes and subsequently migrate 
into tissues where they terminally differentiate into macrophages127. Consistent with this 
view, early studies using total body lethal irradiation followed by bone marrow transplant 
concluded that ATMs were mostly bone-marrow derived11. Subsequent studies aimed to 
reduce monocyte recruitment to the adipose tissue in obesity. Monocyte chemoattractant 
protein 1 (MCP-1) was identified in several studies as one of the inflammatory cytokines 
whose expression increases in obese adipose tissue11,128,129. Whole body genetic deletion 
of MCP-1 was found to produce a modest but significant decrease in ATM content in 
mice fed a high-fat diet for 12-16 weeks115. Similarly, whole body genetic deletion of the 
MCP-1 receptor, CCR2, produced a modest but significant reduction in ATM content in 
mice fed a high fat diet108. This study also employed a short term drug-induced inhibition 
of CCR2 and observed a small but significant difference in ATM content in obese mice 
after 17 days of daily injection with a small molecule inhibitor of CCR2108.  It is 
important to note that three other studies using MCP-1 and CCR2 knockout animal 
models and employing nearly identical experimental conditions failed to demonstrate any 
difference in ATM content in obesity130-132.  
 
Inhibition of osteopontin, an inflammatory cytokine and extracellular matrix protein 
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elevated in obesity, by either genetic deletion or injection of neutralizing antibody, was 
also associated with decreased macrophage content in adipose tissue in obese mice and 
an improvement in insulin sensitivity133,134. Another study employed genetic deletion of 
alpha-4 integrin, which is required for macrophage adhesion to endothelial cells during 
transmigration into tissues114. Myeloid-specific absence of this adhesion marker was also 
associated with a small but significant decrease in ATM content in diet-induced obese 
mouse models114. Likewise, a myeloid-specific knockout of Cbl-associated protein, a 
protein involved in macrophage migration, produced a decreased ATM content in obese 
adipose tissue135. It is critical to note that both of these studies employed total body lethal 
irradiation followed by bone marrow transplant in order to generate the myeloid-specific 
knockout models, and a recent study has shown that irradiation dramatically reduces the 
lifespan of resident macrophages136.  
 On the other hand, as with most any tissue, monocytes can be induced to enter 
adipose tissue. As described above, overexpression of MCP-1 specifically in the adipose 
tissue was associated with an increased macrophage content in the adipose tissue, 
presumably due to increased monocyte recruitment from the blood115,116. Also described 
above, induction of lipolysis has been shown to attract monocytes to adipose tissue in 
lean mice125. However, a recent paper showed that the cells which infiltrate that adipose 
tissue during lipolysis may actually be neutrophils137. It is interesting to note that, unlike 
in lean animals, induction of lipolysis in adipose tissue of obese mice by fasting did not 
stimulate the recruitment of monocytes to adipose tissue138. However, a recent paper 
demonstrated that monocytes labeled with dye and adoptively transferred into obese 
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recipient mice do appear within the adipose tissue within 2-3 days following transfer, and 
more of the dye-labeled monocytes are recruited to adipose tissue in obese mice as 
compared to lean mice139. Importantly, they demonstrated that the recruitment of labeled 
monocytes to adipose tissue was partially dependent on MCP-1 and CCR2139. Overall, 
there is substantial evidence that monocytes can be induced to enter adipose tissue by 
various factors, and that the absence of certain chemokines and adhesion and migration-
related molecules can attenuate the increase of macrophages in adipose tissue that occurs 
in obesity. However, the chemokine studies have reported varied results, and the 
adhesion and migration molecule knockout studies may also be interpreted as attenuation 
of the ability of knockout monocytes to repopulate of the adipose tissue following the 
destruction of resident adipose tissue macrophages by total body lethal irradiation. 
Therefore, we hypothesized that, in the absence of total body lethal irradiation, ATMs 
arise not from circulating monocytes, but from local proliferation in situ.  
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Examples of Local Macrophage Proliferation 
 
Selective Ablation of Monocytes Preserves Tissue Macrophages 
 Monocytes are developed from myeloid precursor cells in the bone marrow, and 
mature monocytes enter the bloodstream and enter the tissues where they terminally 
differentiate into macrophages127,140. It is generally thought that terminally differentiated 
cells are not capable of re-entering the cell cycle to proliferate. However, macrophages 
have long been known to be capable of proliferating in situ and those examples will be 
reviewed below. The best early evidence that tissue macrophages could proliferate locally 
came from experiments that involved using radioactive strontium to deplete bone marrow 
cells141. Strontium is in the same chemical group as calcium, and is stably incorporated 
into hydroxyapatite crystals in bone in a similar fashion to calcium142. Radioactive 
strontium-89 is a beta particle emitter with a half life of over 50 days142. Therefore, 
simply injecting mice with radioactive strontium provided an easy, targeted method to 
deplete bone marrow cells without affecting proliferating cells in other tissues141. This 
represents a key difference from modern day bone marrow depletion studies that employ 
total-body lethal irradiation, which can destroy proliferating cells not only in the bone 
marrow, but in many tissues of the body136. In the strontium study, monocytes were 
depleted to undetectable levels for the duration of the 10-15 day study periods141. Despite 
this profound and prolonged monocytopenia, there were no changes in total number of 
resident macrophages in the lung or peritoneal cavity141. When assayed for proliferation 
markers, 3% of peritoneal and 1.5% of alveolar macrophages were found to be actively 
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synthesizing DNA during a one hour pulse of radioactive thymidine141. These results 
suggested that resident macrophage population renewal under normal circumstances does 
not depend heavily on influx of circulating monocytes. In the sections below, I will 
review the recent studies focused on resident macrophage proliferation which have 
shown that, in several tissues, local proliferation plays a predominant role in maintaining 
tissue macrophage populations, with recruitment of monocytes playing little or no role. 
 
Alveolar Macrophages 
As described above, the 1982 radioactive strontium bone marrow depletion 
studies first identified that alveolar macrophages could proliferate locally. Prior to that 
time alveolar macrophages were believed to be derived from circulating monocytes in 
both mouse143,144 and human145,146. However, these early studies employed total body 
irradiation, which inhibits the proliferation of host cells. Subsequent bone marrow 
transplant studies elucidated that a more gentle, fractionated irradiation regimen 
prevented host macrophages from destruction, and resulted in alveolar macrophages 
remaining of host origin for at least 45 weeks following bone marrow transplant147. 
Protection of the lungs from lethal irradiation with a lead shield prior to bone marrow 
transplant resulted in alveolar macrophages remaining of host origin for the lifetime of 
the mouse, despite reconstitution of resident macrophage populations with donor cells in 
tissues that received irradiation136. Also, in parabiotic mice which are surgically joined to 
share a circulatory system, alveolar macrophages were shown to self-renew with little 
involvement of incoming monocytes148. In humans who received allogeneic bone marrow 
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transplant and whose lungs were repopulated with macrophages of donor origin, donor 
macrophages recruited to lungs also proliferate in situ, resulting in a three-fold increase in 
alveolar macrophage content seven weeks after transplant149.  
In addition to proliferating locally to maintain steady-state macrophage density, 
alveolar macrophages also proliferate in response to inflammatory insults. Instillation of 
carbon particles into the lungs of mice was found to stimulate local alveolar macrophage 
proliferation, which accounted for an increase in macrophage content even in mice 
depleted of monocytes by strontium 89150. Similarly, a recent study demonstrated that the 
massive increase in macrophage content in the lung that occurs during helminth infection 
can arise even in the complete absence of circulating blood monocytes151. They also 
showed that this surprising result was due entirely to the local proliferation of 
macrophages within the lung151. Thus, in the lung, local macrophage proliferation is well 
documented and may be the predominant mechanism for macrophage population renewal 
in the steady state, as well as the mechanism by which macrophage populations increase 
during inflammatory insult.  
 
Langerhans Cells 
 One of the phagocytic, antigen-presenting phagocytic cell type in the epidermis of 
the skin is the Langerhans cell. These cells were originally thought to originate from bone 
marrow-derived cells152 but in 2002 they were shown to be self-renewing within the 
skin153. Using both bone marrow transplant and surgically joined parabiotic mouse 
models, Langerhans cells remained of host origin for the duration of the studies – 18 and 
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6 months, respectively153. Furthermore, this study demonstrated that Langerhans cells 
actively synthesize DNA in the skin, as up to 30% of the Langerhans cells incorporated 
BrdU after a 30 day BrdU exposure153. Only when resident Langerhans cells were 
depleted with UV irradiation or toxic chemicals did replacement of resident Langerhans 
cells with circulating cells of donor origin occur153. However, a follow-up study showed 
that even during the repopulation phenomenon that occurs in damaged skin, circulating 
monocytes enter the inflamed skin and undergo several rounds of proliferation, forming 
clusters of Langerhans cells154. Evidence in humans also supports a role for Langerhans 
cell self-renewal in the skin, as a case study of a human hand transplant showed that skin 
Langerhans cells remained of donor origin even 4.5 years after transplantation155. Taken 
together, these results indicate that under steady state conditions, skin Langerhans cells 
replenish themselves almost entirely through local proliferation in situ, and monocyte 
recruitment only occurs in response to inflammatory insult. Furthermore, even under 
inflammatory conditions, local proliferation of the freshly recruited monocytes plays an 
important role in populating the skin with Langerhans cells.  
 
Kupffer Cells 
 Liver Kupffer cells also are widely believed to be derived from monocytes due to a 
study which demonstrated that Kupffer cells can be derived from blood monocytes 
following total body lethal irradiation156. However, several early publications implicated a 
possible role for local proliferation in the maintenance of the Kupffer cell population in 
mice157-160. Kupffer cells were subsequently shown to indeed have proliferative capacity 
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but that, under steady state conditions, monocyte recruitment was the predominant force 
in maintaining the Kupffer cell population161. On the contrary, one study came to the 
conclusion that under physiological steady state conditions, Kupffer cells are long lived 
and mostly self-renewing162. 
 Interestingly, several groups have reported the Kupffer cells proliferate in response 
to inflammatory insult. Intravenous injection of zymosan has been found to stimulate 
robust local Kupffer cell proliferation within the liver161. This result was later confirmed 
and expanded to show that local proliferation is indeed the predominant force behind 
Kupffer cell hyperplasia in response to zyomsan insult163,164. Similarly, liver injury 
induced by carbon tetrachloride is accompanied by an expansion in the liver macrophage 
population, which has been shown to be due to both local proliferation and monocyte 
recruitment165. Further studies will be required to clarify these seemingly conflicting 
results, but it is clear that to some degree or other, liver macrophages are capable of 
proliferating in situ under both steady state and inflammatory conditions.  
 
Kidney 
Macrophages accumulate in the kidney in various disease states, and there they 
contribute to inflammatory processes that exacerbate kidney injury166. A surprising 
number of studies have reported local macrophage proliferation in kidney inflammation. 
For example, in rat anti-glomerular basement membrane glomerulonephropathy, local 
macrophage proliferation has proven to be the major mechanism by which macrophage 
numbers increase in the glomerulus167. Indeed, measurements of proliferation markers in 
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the macrophages in this and another related study were astoundingly high, with over 60% 
of all macrophages expressing the proliferation marker PCNA at any given time, and the 
30-40% of those cells staining positive for BrdU incorporation after a 3-hour BrdU 
pulse167,168. High levels of local macrophage proliferation have also been documented in 
glomerulonephritis in human patients169. Importantly, proliferating macrophages were 
found to be concentrated in regions of severe tissue damage, suggesting that proliferating 
macs are an important mediator of kidney injury169. Local macrophage proliferation has 
been noted in non-immune-mediated kidney injury models as well, and the association of 
macrophage proliferation with tissue injury and fibrosis was clear in these models also170. 
Importantly, local macrophage proliferation is also the mechanism by which 
macrophages accumulate in the kidney in diabetic nephropathy in obese mice171. 
Furthermore, macrophage accumulation associated with organ rejection in allogeneic 
kidney transplant studies has been shown to be due to initial recruitment of circulating 
monocytes which then undergo local proliferation in situ to increase the macrophage 
content172. Taken together, there is substantial evidence that local macrophage 
proliferation in the kidney represents an important mechanism by which macrophage 
populations increase in kidney diseases. 
 
Atherosclerosis  
Macrophages are an integral cell type in the formation of atherosclerotic 
plaques173, and an impressive number of studies support a role for local proliferation in 
the accumulation of macrophages in the growing plaque. This body of work has even 
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warranted recent reviews on the topic of macrophage proliferation in atherosclerosis174,175. 
Proliferating macrophages within atherosclerotic plaques were first observed in rabbit 
models, using microscopic examination of plaques following pulses of radiolabeled 
thymidine analog or growth-arresting colchicine treatment176,177. Around the same time, 
expression of genes associated with cell proliferation were found to be increased in 
human atherosclerotic plaques, in which macrophages were suggested to be the 
predominant proliferating cell type178,179. Myeloid-specific deletions of the tumor-
suppressor genes p27 and retinoblastoma caused increased intimal macrophage 
proliferation and accelerated atherosclerosis development in apolipoprotein E knockout 
animals180,181. Similarly, mutation of the cyclin-dependent kinase inhibitor 2A gene in 
myeloid cells in low-density-lipoprotein (LDL) receptor knockout animals caused 
increased macrophage proliferation and exacerbated atherosclerosis182. While several 
other reports using the tumor suppressor gene p53 yielded both positive183-185 and 
negative186,187 results in regards to macrophage proliferation, it is clear that macrophage 
proliferation in situ is involved in plaque formation and the maintenance of macrophage 
populations in atherosclerotic plaques.  
 
Macrophage Proliferation in Other tissues 
 Macrophages in several other tissues have been documented to proliferate locally to 
maintain macrophage populations in the steady state. For example, the spleen is one of 
the largest repositories of macrophages in the body, and local proliferation may account 
for up to half of the macrophage content in the spleen188,189. Microglia, a subtype of 
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macrophages in the central nervous system, have been shown by several groups to 
proliferate locally190-192. Peritoneal macrophages have also been shown to have 
proliferative capacity in vitro as well as in vivo193-195. Local macrophage proliferation has 
been documented in various other disease models including arthritis196,197, and finally in 
macrophages associated with tumors198-201. Indeed, locally proliferating macrophages have 
recently been identified in high-grade breast cancers and indicate a poor prognosis202,203.  
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Summary and Objectives  
 The adipose tissues in obese, insulin resistant mice and humans accumulate 
inflammatory cells, including macrophages, which secrete cytokines and other factors 
that can modulate adipocyte function. These adipose macrophages are thought to 
originate from bone marrow-derived monocytes, which infiltrate the tissue from the 
circulation. However, genetic deletion of molecules thought to be important in the 
recruitment of monocytes to adipose tissue produced either a modest decrease in adipose 
tissue macrophage content compared to controls, or no decrease in adipose tissue 
macrophage content at all. 
 Despite the fact that macrophages are generally thought to be a terminally 
differentiated cell type, there are many examples of macrophage proliferation locally 
within tissues. Local proliferation can be the predominant way in which tissue 
macrophages maintain normal density under basal conditions, and local proliferation can 
account for the massive increases in macrophage tissue density that occur in certain 
inflammatory conditions. However, the role of local macrophage proliferation in adipose 
tissue inflammation in the obese state has not been thoroughly investigated.  
 Therefore, we sought to elucidate the role of local macrophage proliferation in 
maintaining macrophage populations in the adipose tissue of lean and obese mice. Using 
both genetic and diet-induced obese mouse models, we examined macrophage 
populations for proliferative markers in the adipose tissue under steady-state lean and 
obese conditions, as well as during weight loss. To clarify the origin of adipose tissue 
macrophages, we studied adipose tissue macrophage population dynamics in the setting 
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of monocyte depletion. Finally, we made several initial efforts into elucidating the factors 
that may be stimulating local macrophage proliferation in the adipose tissue.  
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Chapter II: Local proliferation of adipose tissue macrophages  
in obesity-associated inflammation 
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Abstract 
 
The adipose tissues in obese, insulin resistant mice and humans accumulate 
inflammatory cells, including macrophages, which secrete cytokines and other factors 
that can modulate adipocyte function. These adipose macrophages are thought to 
originate from bone marrow-derived monocytes, which infiltrate the tissue from the 
circulation. Here we show that a significant fraction of macrophages unexpectedly 
undergo cell division locally within adipose tissue, as detected by Ki67 expression and 5-
ethynyl-2’-deoxyuridine incorporation. Adipose macrophages, but not those in other 
tissues, displayed dramatically increased proliferation in both genetic and diet-induced 
mouse models of obesity. Importantly, depletion of blood monocytes over several days 
had no impact on adipose tissue macrophage content. Conversely, weight loss and 
lipolysis specifically inhibited macrophage proliferation in the adipose tissue of obese 
animals. These results reveal that proliferation in situ is an important process by which 
macrophages accumulate in inflamed adipose tissue in obesity, and could have 
therapeutic implications for strategies to improve insulin sensitivity.  
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Introduction 
 
The prevalence of insulin resistance and type 2 diabetes mellitus (T2D) has been 
rapidly rising worldwide over the past three decades, particularly in developing 
countries204. Obesity can induce an insulin-resistant state in adipose tissue, liver, and 
muscle and is a strong risk factor for the development of T2D14,15,205-207. In obese patients, 
the inability to appropriately expand subcutaneous adipose tissue leads to ectopic lipid 
deposition in non-adipose tissues (e.g. liver and muscle) and may be an underlying cause 
of insulin resistance208-213. Immune cells, including macrophages, accumulate in massive 
numbers in the adipose tissues of obese mice and human subjects11,214-216. It is increasingly 
appreciated that accumulation of macrophages in adipose tissue correlates with a chronic 
inflammatory state that ultimately impairs adipocyte function and may contribute to the 
development of insulin resistance3,11,15,81,217,218. Consistent with this concept, macrophage 
numbers in adipose tissue correlate with systemic insulin resistance even in obese human 
subjects that are matched for BMI109,219-221. Macrophages and other immune cells in 
adipose tissues also have beneficial effects of removing cellular debris107 and controlling 
lipolytic responses in adipocytes125.  
 
Macrophages infiltrating into adipose tissue have been reported to be mostly derived 
from the bone marrow and there is evidence that monocyte recruitment to the adipose 
tissue increases in obesity11,139. Adipocytes have been shown to produce a wide range of 
factors, such as the chemokine monocyte chemoattractant protein 1 (MCP-1) that may 
recruit monocytes to adipose tissue. Both the production of MCP-1 and the expression of 
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its receptor CC-motif chemokine receptor-2 (CCR2) are enhanced by obesity116,130. 
However, genetic deletion of MCP-1 and CCR2 in mice produced either a modest 
decrease in adipose tissue macrophage (ATM) content compared to controls108,115, or no 
effect that could be detected131,132. Perhaps this is due to other pathways of macrophage 
migration that operate independently of the MCP-1 pathway. However, these results 
might also be explained by the possibility that resident macrophages have a prolonged 
lifespan or proliferate in situ in the adipose tissue. Although terminal differentiation of 
mammalian cells typically results in reduced proliferative capacity, there is evidence that 
cells of the mononuclear phagocyte system, including macrophages, can self-replicate in 
the periphery both during development and in the adult222-224. Indeed, local macrophage 
proliferation has been demonstrated in kidney, atherosclerotic plaques, skin and lung in 
animals and humans151,169,176,182,225.   
 
The present study was designed to test the hypothesis that significant macrophage cell 
division also occurs within adipose tissue in mice, since no data are available on this 
important question.  Here we show that a fraction of ATMs in obese mice display the 
proliferation marker Ki67, a protein expressed during all active phases of the cell cycle 
but not in non-dividing cells226. Genetic and diet-induced obesity greatly increased 
macrophage proliferation in adipose tissue, but not in other tissues studied. Furthermore, 
approximately 5% of macrophages within epididymal adipose tissue of obese mice were 
found to be in S-phase during a three-hour pulse of the more stringent cell division 
marker, 5-ethynyl-2’-deoxyuridine (EdU), and nearly 50% of all macrophages had 
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proliferated over the course of an 80 hour EdU exposure, even when circulating 
monocytes had been depleted. These results suggest the unexpected concept that local 
macrophage proliferation contributes to the overall macrophage accumulation and 
adipose tissue inflammation in the insulin resistant state.  
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Results 
 
Adipose tissue macrophages express the cell division marker Ki67.  
To study macrophage accumulation in adipose tissue of obese mice, we used 8 to 12-
week old genetically obese (ob/ob) male mice and their lean control wild-type (WT) 
littermates. To confirm that the ob/ob mice were insulin resistant and obese, we measured 
body weights and performed glucose tolerance tests (GTT) (Figure 2.1 A-B). The 
average body weight of the ob/ob mice was approximately 15 g, or 50% higher than that 
of WT mice, and this was associated with significantly decreased glucose tolerance 
(Figure 2.1 A-B). We isolated the stromal-vascular fraction (SVF) from subcutaneous 
(inguinal) and visceral (epididymal) fat pads, which contains all cells of the adipose 
tissue except adipocytes, and analyzed it using flow cytometry. The SVF was stained 
with antibodies against two macrophage markers, F4/80 and CD11b. However, these 
proteins are also expressed in other immune cells, such as eosinophils and 
neutrophils95,227. Therefore, we also stained the SVF with antibodies against the 
eosinophil marker, Siglec-f, and a neutrophil marker, Gr-1. The macrophage population 
in the adipose tissue was defined as F4/80+/CD11b+/Siglec-f–/Gr-1– (for the complete 
gating scheme see Supplementary Figure 2.1). Consistent with published studies11,105, 
we observed a significant 2-3 fold increase in macrophage content in the adipose tissue of 
ob/ob compared to WT mice in both subcutaneous and visceral fat pads (Figure 2.1 C-
D).  
  To test whether local macrophage proliferation also contributes to macrophage 
accumulation in the adipose tissue, we stained the SVF cells with an antibody against the 
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proliferation marker Ki67, which is a protein expressed during all active phases of the 
cell cycle226. Surprisingly, Ki67 signal was detected in approximately 2.3% of epididymal 
ATMs of lean mice, and in 10% of ATMs of ob/ob mice (Figure 2.1 E-F). Similar 
percentages of macrophages from subcutaneous adipose tissue were Ki67+ as well 
(Figure 1F). We then performed immunofluorescence microscopy on plated SVF cells 
from epididymal fat pads of ob/ob mice. Figure 2.1 also shows images of macrophages 
(F4/80, red) expressing Ki67 (green) in their nuclei (DAPI, blue) (Figure 2.1 G). 
Microscopy revealed a similar percentage (approximately 10%) of Ki67+ macrophages as 
seen with flow cytometry (data not shown). High magnification images reveal 
macrophages in various stages of division (Figure 2.1 G). Furthermore, Ki67 was often 
found in multinucleated macrophages (Figure 2.1 G). Next, AT sections from ob/ob 
mice were stained with antibodies against F4/80 (red) and Ki67 (green) and analyzed by 
microscopy (Figure 2.1 H-I). Figure 2.1 G and H show Ki67 in F4/80 positive cells in a 
region of the epididymal AT rich in macrophages termed crown-like structures (CLS). 
Taken together, these results show by both flow cytometry and microscopic analysis that 
macrophages express the proliferation marker Ki67 in the AT and to a higher degree in 
response to obesity in mice caused by either genetic mutation or a diet high in fat. 
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Figure 2.1. Ki67 expression in adipose tissue macrophages of lean and obese mice. 
(A) Body weights and (B) GTT of WT (●) and ob/ob (■) mice, n=5. (C-F) SVF from 
visceral and subcutaneous adipose tissue of WT and ob/ob mice was isolated and 
analyzed by flow cytometry. (C) Representative flow cytometry dot plots of SVF from 
epididymal adipose tissue. (D) Percentage of macrophages in SVF. (E) Representative 
flow cytometry dot plots of macrophages stained with Ki67. (F) Percentage of 
macrophages expressing Ki67.  n=30-31 from 6 independent experiments for epididymal 
and n=10 from 2 independent experiments for inguinal fat pads. All graphs are expressed 
as mean ± s.e.m. Statistical significance was determined by Student’s t-test. For GTT, 
statistical significance was determined by ANOVA and Tukey post test. **p<0.01; 
***p<0.001. (G-I) Microscopy of plated SVF (G) and adipose tissue sections (H-I) 
stained with antibodies against F4/80 (red) and Ki67 (green). Nuclei were stained with 
DAPI (Blue). (G) 63x magnification image of macrophages stained with Ki67 (arrows). 
Scale bar = 5 μm. (H-I) 20x magnification images of crown-like structures from ob/ob 
mice. Scale bar = 40 μm.  
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Macrophages proliferate locally in adipose tissue. 
To test whether macrophages undergo cell division within adipose tissue, we injected WT 
and ob/ob mice with the nucleoside analog to thymidine, EdU. While Ki67 is expressed 
during all active phases of the cell cycle, EdU is only incorporated into DNA during the 
S-phase. Three hours following EdU injection in mice, the SVF cells of epididymal fat 
pads were isolated and analyzed by flow cytometry. Approximately 1% of ATMs in lean 
mice and about 5% of the macrophages in the obese mice had gone through S-phase as 
measured during a 3-hour pulse of EdU (Figure 2.2 A-B). Mice were also injected with 
another nucleoside analog of thymidine, 5-bromo-2'-deoxyuridine (BrdU) and 
immunohistochemistry on epididymal adipose tissue of ob/ob mice was performed 
(Figure 2.2 C). As shown in Figure 2.2C, ob/ob adipose tissue contains regions known to 
be enriched with macrophages called crown-like structures (CLS; denoted by arrows). 
BrdU staining (denoted by arrowheads) was observed in these structures (Figure 2.2 C). 
 
To test whether EdU+ macrophages in adipose tissue derived from EdU+ macrophages 
that infiltrated from the blood rather than cells propagating within the tissue, we also 
examined EdU incorporation in blood monocytes (Figure 2.2 D-E). In these same mice, 
blood was collected via cardiac puncture and analyzed by flow cytometry. Monocytes 
were positively identified by expression of CD11b, F4/80, and Ly6C (for complete blood 
monocyte gating scheme see Supplementary Figure 2.2 A). We failed to detect any 
EdU incorporation in blood monocytes within the 3-hour pulse, suggesting that EdU+ 
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macrophages seen in the adipose tissue are not recently recruited blood monocytes 
(Figure 2.2 D-E).  
 
To further ensure that the proliferating macrophages in the adipose tissue were not EdU+ 
blood monocytes, we studied the capacity of ATMs to proliferate ex vivo. SVF cells 
isolated from epididymal adipose tissue of lean and obese mice were plated and treated 
with EdU for three hours. The cells were then stained and analyzed by flow cytometry. 
Approximately 0.3% of the ATMs from lean mice were EdU+, while greater than 2% 
were positive in macrophages from obese mice (Figure 2.2 F-G). These results suggest 
that the ATMs have the inherent capacity to proliferate ex vivo, independently of blood 
monocyte recruitment. Taken together, these results suggest that proliferating 
macrophages present in adipose tissue are not recently recruited blood monocytes that 
were already dividing. 
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Figure 2.2. Macrophage cell division in adipose tissue detected by EdU 
incorporation in lean and obese mice. Mice were treated with EdU and epididymal 
adipose tissue SVF and blood were collected 3 hours after treatment and analyzed by 
flow cytometry. (A) Representative flow cytometry dot plots of adipose tissue 
macrophages and (D) blood monocytes, and the corresponding bar graphs (B) and (E). 
(C) Left images, 20x magnification of epididymal adipose tissue of WT and ob/ob mice. 
Arrows denote crown-like structures (CLS). Scale bar = 50 μm. Right image, 100x 
magnification image of a CLS in ob/ob epididymal adipose tissue containing cells 
staining positive for BrdU (arrowheads). Scale bar = 10 μm. BrdU was injected 3 hours 
before tissue isolation. (F-G) Adipose tissue SVF was isolated and plated in media 
containing 10 μM EdU. Three hours later cells were harvested and analyzed by flow 
cytometry. (F) Representative dot plots of ex vivo macrophage EdU incorporation and 
(G) corresponding rates. All graphs depict mean of EdU+ cells ± s.e.m. Statistical 
significance was determined by Student’s t-test. For both sets of experiments n=14-15 
mice/group from 3 independent experiments. ***p<0.001. 
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Obesity increases macrophage proliferation specifically in adipose tissue.  
To test whether obesity stimulates macrophage proliferation in tissues other than adipose 
tissue, we analyzed the proliferation rate of macrophages in spleen and liver following a 
3-hour pulse of EdU. The tissues were digested and, as expected, mononuclear cells 
analyzed by flow cytometry exhibited a higher rate of proliferation in the epididymal 
adipose tissue of ob/ob compared to WT mice (Figure 2.3 A). Interestingly, in addition 
to macrophages, non-macrophage (F4/80–) cells in the adipose tissue also showed an 
increased rate of proliferation with obesity. The overall rate of EdU incorporation during 
the pulse into all adipose tissue SVF cells was approximately 0.5% in lean and 4.5% in 
obese mice (Figure 2.3 A). Conversely, we observed that less than 2% of all cells were 
EdU+ in spleen and liver, and there was no difference in EdU+ cells between lean and 
obese mice (Figure 2.3 B-C).  
 
Although macrophage content increased with obesity in adipose tissue (Figure 2.1 C), 
macrophage content did not increase in spleen or liver in ob/ob mice compared to WT 
mice (data not shown; for spleen and liver macrophage gating schemes see 
Supplementary Figure 2.3 B-C). Figure 2.3D shows the rate of proliferation exclusively 
for macrophages in each tissue in lean and obese states. Importantly, while obesity was 
associated with a higher rate of macrophage proliferation in adipose tissue, it did not 
affect the EdU incorporation rate in spleen, liver or blood macrophages. These results 
suggest that proliferation may contribute to the increased macrophage accumulation in 
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the adipose tissue in obesity. Furthermore, something unique about the adipose tissue 
microenvironment may stimulate macrophage proliferation during obesity. 
 
  
  
50 
 
  
51 
 
 
 
 
 
 
Figure 2.3. Obesity does not stimulate macrophage proliferation in liver or spleen. 
Mice were treated with EdU and (A) adipose tissue, (B) spleen and (C) liver were 
collected and digested 3 hours after treatment. All cells were stained and analyzed by 
flow cytometry. Representative dot plots depict the EdU incorporation into all cells of the 
respective tissues. (D) Mean EdU incorporation rate of the macrophages of each tissue ± 
s.e.m.; n= 14-15 from 3 independent experiments for adipose tissue and blood, and n=9-
10 from 2 independent experiments for spleen and liver. Statistical significance was 
determined by Student’s t-test. ***p<0.001. 
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To study the contribution of monocyte recruitment in ATM accumulation during obesity, 
we depleted blood monocytes in ob/ob mice by intravenous (i.v.) injection of clodronate- 
loaded liposomes, which induce apoptosis once ingested by monocytes228. Consistent 
with the literature, clodronate-liposome i.v. injection depleted about 80% of blood 
monocytes 16 hours after injection compared to PBS-liposome injection (Figure 2.4 A-
B). We then injected ob/ob mice every 16 hours with clodronate-liposomes to maintain 
blood monocyte depletion and measured macrophage content in the epididymal AT. 
Unexpectedly, ATM absolute number (50 hours, PBS-lipo 3.78 ± 0.37 vs. clodronate-lipo 
3.88 ± 0.35; 96 hours, 4.54 ± 0.60 vs. clodronate-lipo 3.36 ± 0.11 (x106 cells/g of 
epididymal AT)) and ATM percentage in the SVF were unchanged with clodronate-
liposome treatment even after prolonged blood monocyte depletion (Figure 2.4 C). 
These data raised the possibility that the increase in macrophages seen during obesity was 
largely the result of proliferation of the resident population. Therefore, ob/ob mice were 
given EdU in drinking water during monocyte depletion as depicted in diagram in Figure 
2.3D. Thirty-two hours after EdU exposure, approximately 28% of macrophages were 
EdU+ in the AT of ob/ob mice injected with PBS-liposomes (Figure 2.4 E-F). Eighty 
hours after EdU exposure, about half of the macrophages in the AT of ob/ob mice 
injected with PBS-liposomes had incorporated EdU (Figure 2.4 E-F). Importantly, 
depletion of blood monocyte had no effect on macrophage proliferation as observed by 
the EdU incorporation in the epididymal AT of ob/ob mice injected with clodronate-
liposomes (26% after 32 hr and 46% after 80 hr) (Figure 2.4 E-F). These results suggest 
that resident macrophages proliferate independently of monocyte recruitment. However, 
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recently recruited macrophages may also proliferate in AT of obese mice since a recent 
study showed that 5% of labeled blood monocytes, transferred from donor into recipient 
mice, express Ki67 in the host AT two days after transfer139. 
 
We next analyzed the proliferative capacity of macrophages in the epididymal AT depot, 
where most of the macrophage expansion occurs in obesity, versus the subcutaneous AT 
depot. EdU incorporation by macrophages was significantly higher in the epididymal AT 
of ob/ob compared to WT mice (Figure 2.4 G). However, although Ki67 expression is 
higher (Figure 2.1), no difference in EdU incorporation was observed in macrophages in 
subcutaneous AT of ob/ob compared to WT mice after 80 hours of EdU exposure 
(Figure 2.4 G). Epididymal ATM proliferation rates were also higher than in 
subcutaneous ATMs in the PBS- and Clodronate-liposome-treated mice (Supplementary 
Figure 2.3 B). Unlike in the epididymal adipose tissue, the content of EdU+ ATMs in the 
subcutaneous depots did not dramatically increase between 32 hours and 80 hours of EdU 
exposure, possibly indicating macrophage turnover begins to occur within this time 
period (Supplementary Figure 2.3 B). Taken together, these results suggest that 
macrophage proliferation plays a major role in the increase in macrophage content that 
occurs in the adipose tissue in obesity. 
 
While macrophage sub-populations in the AT may have overlapping marker expression 
profiles, it is generally thought that CD11c expression is characteristic of pro- 
inflammatory macrophage subtypes117. Therefore, we analyzed the rate of proliferation of 
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pro- (CD11c+) and anti- (CD11c⎯) inflammatory macrophages (Supplemental Figure 2.3 
C). Although proliferation of anti-inflammatory macrophages has been shown to be a 
signature of TH2 inflammation in the lung151, we failed to observe any difference in the 
rate of proliferation of macrophage population subtypes. This suggests that obesity 
increases macrophage proliferation rate independently of their inflammatory state. 
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Figure 2.4. Adipose tissue macrophages proliferate independently of monocyte 
recruitment. ob/ob mice were i.v. injected with either PBS-liposomes or clodronate- 
liposomes every 16 hours. Small amounts of blood were taken at the end of several of the 
16h periods and immediately before subsequent liposome injection to ensure monocyte 
depletion was continuous. Untreated mice did not receive any injection. (A) Example 
flow cytometry dot-plots of CD11b+ blood cells show depletion of monocytes, and (B) 
the quantitation of blood monocytes expressed as a percentage of total blood cells. n=10 
for 16h-50h of liposome treatment and n=4-5 for the 96h time point. (C) Macrophage 
content in the AT of PBS-liposome (PBS-Lipo) and clodronate-liposome (Clod-Lipo) 
treated ob/ob mice; n=5 mice per group. 18 hours after initial injection, the mice were 
given drinking water containing EdU. (D) Diagram representing experimental design of 
treatment. (E) Representative flow cytograms and (F) quantification of EdU 
incorporation into ATMs during 32h and 80h of exposure to EdU drinking water in PBS-
liposome-treated and monocyte-depleted clodronate-liposome-treated ob/ob mice. (G) 
Quantification of EdU incorporation into ATMs during 80h of exposure to EdU drinking 
water in EPI and SQ adipose depots in lean WT and ob/ob obese mice. n= 5 mice per 
group. 
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Differential effect of obesity on proliferation of diverse immune cell types in adipose 
tissue. 
We next examined whether obesity modulated the proliferation of eosinophils and 
neutrophils, two other immune cell types thought to be involved in the development of 
insulin resistance95,227. Consistent with prior reports95, we found that eosinophil content 
relative to macrophages in the adipose tissue decreased with obesity (Supplementary 
Figure 2.4 A-B). We also observed a significant decrease in the expression of a cytokine 
secreted by eosinophils, interleukin 4 (IL-4), in the epididymal adipose tissue of obese 
compared to lean mice (Supplementary Figure 2.4 D).  Neutrophil content in adipose 
tissue was not significantly different between WT and ob/ob mice (Supplementary 
Figure 2.4 E-F). Importantly, neither eosinophils nor neutrophils exhibited any 
significant EdU incorporation (Supplementary Figure 2.4 C and G), suggesting that 
these cells types do not proliferate in the adipose tissue. These results suggest that obesity 
does not stimulate proliferation of all cells in the adipose tissue, but selectively stimulates 
proliferation of specific cell types including macrophages. 
 
Macrophage proliferation decreases with weight loss.  
We next asked if weight loss in mice could cause a corresponding decrease in 
macrophage accumulation in adipose tissue. Mice were fed a high fat diet (HFD) for 7-14 
weeks. At the end of the HFD period, mice had become obese and glucose intolerant 
(Supplementary Figure 2.5 A). We examined the macrophage content in the adipose 
tissue and the rate of macrophage proliferation. ATM content was approximately 20% of 
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the SVF of epididymal adipose tissue in mice fed a normal chow diet (ND) and about 
50% in mice fed a HFD (Figure 2.5 A-B). Flow cytometry analysis on SVF showed that 
3.2% of ATMs were Ki67+ in the ND-fed mice while approximately 14% of the ATMs 
were Ki67+ in the HFD-fed mice (Figure 2.5 C-D). Macrophage proliferation in 
subcutaneous adipose tissue exhibited similar decreases to those seen in epididymal 
ATMs (Supplementary Figure 2.5 E-F). To induce weight loss, HFD-fed mice were 
fasted overnight. Fasted mice lost between two and three grams on average, which was 
equal to 5-10% of their total body weight (Figure 2.5 F). The macrophage content in the 
adipose tissue was unchanged with weight loss as determined by flow cytometry (Figure 
2.5 B and Supplementary Figure 2.5 D). Consistently, the expression of macrophage 
markers (F4/80, CD11b, CD11c and TNF-α) was unchanged as measured by real time 
PCR (Figure 2.5 E). In  the fasted mice, weight loss was associated with a significant 
decrease in ATM proliferation (Figure 2.5 D). A similar decrease in Ki67 staining was 
seen in ATMs from the subcutaneous adipose tissue of the mice that lost weight 
(Supplementary Figure 2.5 F). To test another model of weight loss, we treated ob/ob 
mice with the β3-adrenoceptor agonist, CL-316,243, which is known to induce fatty acid 
release from adipocytes in vivo229-231. We observed that CL-316,243 treatment of wild-
type animals was associated with a significant increase in CD11b+ cells in the epididymal 
adipose tissue, but no increase was observed in ob/ob animals (Figure 2.5 G-H). 
However, treatment of ob/ob animals with CL-316,243 did cause a slight but significant 
decrease of ATM proliferation (Figure 2.5 I). Taken together, these results suggest that 
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local ATM proliferation is a dynamic process that increases with weight gain and 
decreases with weight loss.  
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Figure 2.5. Adipose tissue macrophage proliferation decreases with weight loss.  
Mice were fed a HFD or ND for 7-14 weeks. n=17-20 mice/group from 4 independent 
experiments. Some HFD-fed mice were fasted overnight (FAST); n=8 mice/group from 2 
independent experiments. SVF cells from epididymal fat pads were isolated and analyzed 
by flow cytometry. (A) Representative flow cytometry dot plots of the SVF F4/80 and 
CD11b staining. (B) Percentage of macrophages in SVF for ND, HFD and fasted mice. 
(C) Representative flow cytometry dot plots of Ki67 staining in ATMs. (D) Percentage of 
macrophages positive for Ki67 in ND, HFD and fasted mice. (E) Real-time PCR analysis 
of gene expression in the whole adipose tissue of the weight loss groups and of the ND 
control mice. (F) Weight change for HFD and fasted mice over the 24 hour study period. 
(G-I) WT and ob/ob mice were injected with PBS or CL-316,243 and epididymal adipose 
tissue was harvested 24 hours later. (G) Representative flow cytometry dot plots of SVF 
and (H) percentage of CD11b+ cells in the SVF of PBS and CL-injected mice. (I) 
Percentage of macrophages positive for Ki67 in WT and ob/ob mice treated with PBS or 
CL. All graphs are expressed as mean ± s.e.m. Statistical significance was determined by 
Student’s t-test. *p<0.05; **p<0.01; ***p<0.001. 
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Discussion 
 
The major finding presented here is that macrophages undergo significant cell division 
locally within visceral and subcutaneous adipose tissues of obese mice, suggesting that in 
situ proliferation is a mechanism by which ATMs accumulate in this tissue. Using flow 
cytometry and immunofluorescence microscopy, we readily detected the presence of two 
cell proliferation markers, Ki67 and EdU, in SVF cells isolated from adipose tissue. 
These analyses revealed that 2-4% of ATMs in lean and 10% of ATMs in ob/ob mice 
express the proliferation marker Ki67 (Figure 2.1). Importantly, Ki67+ macrophages 
were identified within the adipose tissue in crown-like structures (Figure 2.1). Similarly, 
a 3-hour in vivo pulse with the thymidine analog EdU showed that nearly 5% of 
macrophages in epididymal adipose tissue of ob/ob mice had gone through the S-phase of 
cell division (Figure 2.2). Importantly, EdU+ macrophages in ob/ob mouse adipose tissue 
are not recently recruited EdU+ blood monocytes, as no EdU staining in blood monocytes 
could be detected in this 3-hour period (Figure 2.2). Furthermore, ATMs isolated from 
adipose tissue continued to proliferate ex vivo, independently of monocyte recruitment 
(Figure 2.2).  The data in Figures 2.1 and 2.2 thus document a remarkable enhancement 
of macrophage proliferation within adipose tissue in response to obesity in mice caused 
by either genetic mutation or a diet high in fat. Interestingly, the apparent rate of 
macrophage proliferation was lower in SVF ex vivo than when measured by 
administration of EdU in vivo. This suggests either that the adipose tissue environment is 
necessary for macrophage proliferation or that blood monocytes infiltrate the adipose 
tissue and then proliferate locally soon after their recruitment. This latter hypothesis is 
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supported by a recent study by Oh et al. showing that 5% of labeled blood monocytes, 
transferred from donor into recipient mice, express Ki67 in the host adipose tissue two 
days after transfer139. Macrophages in the skin have also been reported to be able to 
derive from blood monocytes that proliferate locally within the skin shortly after 
recruitment154. 
 
To determine the relative contribution of incoming monocytes versus local proliferation 
of macrophages to total ATM content, we depleted blood monocytes using clodronate 
liposomes. Over the course of 4 days, we maintained monocyte depletion at or better than 
80% depletion by injecting clodronate liposomes every 16 hours. By assaying blood 
monocyte content at the end of each 16 hour period (immediately before the subsequent 
injection), we ensured that the blood monocyte content never recovered beyond what was 
measured. Surprisingly, despite monocyte depletion for a total of at least 80 hours, we did 
not see a decrease in ATM content in epididymal or subcutaneous adipose tissue (Figure 
2.5 and Supplementary Figure 2.3). As soon as the monocytes were depleted (beginning 
after the second clodronate injection), these same mice were treated with EdU in the 
drinking water.  This allowed us to follow the proliferation of macrophages in the adipose 
tissue both with and without monocyte depletion. At 32 hours of EdU exposure, 
approximately 27% of all ATMs had proliferated, and after 80 hours of EdU exposure 
around 50% of all macrophages in the adipose tissue were positive for EdU. Amazingly, 
these rates were the same with or without monocyte depletion, meaning that the 
proliferating cells were not freshly recruited monocytes. This is consistent with a recent 
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report which noted that freshly recruited monocytes do not proliferate to an appreciable 
degree in the adipose tissue of obese mice139. Interestingly, the accumulation of EdU+ 
macrophages in the adipose tissue does not increase in a linear way over time. For 
example, 4.5% of macrophages were EdU+ after three hours of exposure (Figure 2.2), 
and if this rate were to increase in a linear way, 100% of adipose tissue macrophages 
would be expected to be EdU positive after 67 hours of EdU exposure. However, it 
required 80 hours of exposure to reach 47% of ATMs positive for EdU (Figure 2.4). This 
effect was most pronounced in the subcutaneous adipose tissue, in which little additional 
accumulation of EdU+ macrophages was seen after the first 32 hours of EdU exposure, 
despite the presumably constant rate of macrophage proliferation (Figure 2.4). This 
result implies that, at some point, EdU+ macrophages are leaving the adipose tissue at the 
same rate as they are appearing, with the total EdU+ macrophage content in the adipose 
tissue at equilibrium correlating with the average macrophage residence time in the 
adipose tissue. This raises the possibility that not only is macrophage proliferation 
increased, but macrophage death or efflux out of the adipose tissue is slowed in obesity. 
This is conceptually consistent with a recent report which showed that insulin resistance 
is associated with decreased macrophage trafficking in the adipose tissue138. Our results at 
least suggest that this is the case and that macrophage turnover is slowed particularly in 
epididymal adipose tissue vs. subcutaneous adipose tissue, consistent with epididymal 
adipose tissue being more inflamed. Additional studies will be required to elucidate the 
precise mechanisms by, and rates at which, macrophages leave the adipose tissue. 
Overall, these results suggest that local proliferation, not recruitment of circulating 
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monocytes, is the predominant process by which the large population of macrophages 
present in the obese adipose tissue is maintained in the steady state.  
 
Recently, CD8+ T-cells have been shown to have an increased rate of proliferation when 
co-cultured with adipose tissue of obese compared to lean mice97. In our experiments, 
some but not all cell types in adipose tissue had an increased proliferation rate in obese 
mice. For instance, eosinophils and neutrophils, which have been reported to play a role 
in the development of insulin resistance95,227 did not proliferate within adipose tissue of 
either lean or obese mice (Supplementary Figure 2.4). While both eosinophils and 
neutrophils have been shown to have some proliferative capacity outside of the bone 
marrow232,233, we failed to detect any EdU incorporation into these cells within adipose 
tissue (Supplemental Figure 2.4). Importantly, we observed similar rates of proliferation 
in macrophages expressing the marker CD11c and in those negative for CD11c 
(Supplemental Figure 2.3). While macrophage sub-populations in the adipose tissue 
may have overlapping marker expression profiles, it is generally thought that CD11c 
expression is characteristic of pro-inflammatory macrophage subtypes112,118,121. Although 
proliferation of anti-inflammatory (CD11c-) macrophages has been shown to be a 
signature of TH2 inflammation in the lung151, our results suggest that this is not the case in 
adipose tissue macrophages. 
 
The data presented in Figure 2.3 reveal a striking tissue specificity of the effect of obesity 
on ATM proliferation since no change in cell division of macrophages could be detected 
in spleen or liver of obese mice. These findings imply that the adipose tissue micro-
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environment in obesity is important for macrophage proliferation. A recent study showed 
that IL-4 secreted by eosinophils in lung stimulates macrophage proliferation during 
infection151. Interestingly, eosinophils are present in the adipose tissue and secrete IL-495. 
Consistent with Wu et. al.95, we found that eosinophil content as well as IL-4 expression 
in adipose tissue decrease with obesity (Supplementary Figure 2.4), suggesting that IL-
4 may not be the signal that stimulates ATM proliferation in obesity. However, studies 
focusing on the role of IL-4 in ATM proliferation would require IL-4 treatment in vivo as 
well as genetic deletion of this cytokine in mice. In the macrophage cell line RAW 264.7, 
fatty acids have been shown to increase proliferation234. To test this hypothesis in vivo, 
we treated ob/ob mice with the β3-adrenoceptor agonist, CL-316,243, which is known to 
induce fatty acid release from adipocytes in vivo229-231. We observed that treatment of 
ob/ob animals with CL-316,243 caused a slight but significant decrease of ATM 
proliferation, suggesting that free fatty acid may decrease proliferation in vivo (Figure 
2.5). Additional investigation will be required to elucidate the mechanism by which the 
adipose tissue offers a unique and favorable environment for macrophage proliferation.  
 
The origin of ATMs has previously been attributed to recruitment of blood monocytes 
into adipose tissue based on one study using a bone marrow chimera11. In the study by 
Weisberg, et al.11, bone marrow from donor mice was injected into recipient mice after 
depletion of immune cells by irradiation. Six weeks later, the majority of the ATM 
population was composed of donor marrow-derived cells11. However, it has been shown 
that irradiation dramatically reduces the lifespan of resident macrophages136. In tissues 
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that are shielded from radiation, macrophages remain completely host-derived for at least 
8 months despite reconstitution with donor marrow136. Jenkins et al. showed that 
shielding the lung from irradiation followed by bone-marrow transplant from donor mice 
generates a mixed chimerism in peripheral blood monocytes, but only a low percentage 
of pleural macrophages were of donor origin151. This demonstrated that little replacement 
of these cells occurred from the bone marrow under steady-state conditions151. This 
provides strong evidence that macrophages proliferate locally in tissues both to maintain 
the macrophage density in basal condition, and to increase it during infection. We have 
shown here that macrophages also proliferate locally in the adipose tissue in the basal 
state, and that ATM proliferation increases in the inflammatory setting of obesity. 
 
Using mice fed a HFD we confirmed that weight gain induces a marked increase in ATM 
content and proliferation (Figure 2.5). Using overnight fasting, we tested whether 
weight-loss also regulates ATM proliferation. Although fasting-induced lipolysis has 
been shown to increase ATM content in lean mice125, a recent study showed that fasting 
does not increase ATM content in obese animals138. Consistently, our study showed that 
after an overnight fast ATM content did not change in HFD-fed mice (Figure 2.5). 
Similarly, lipolysis induced by treatment with the β3-adrenoceptor agonist, CL-316,243 
failed to induce macrophage accumulation in the adipose tissue of ob/ob mice (Figure 
2.5). In contrast, CL-316,243 treatment in lean mice induced a massive immune cell 
infiltration in the epididymal adipose tissue (Figure 2.5). It is interesting to note that both 
weight loss models (overnight fast and CL-316,243 treatment) were associated with a 
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significant decrease in the rate of ATM proliferation in obese mice, but had no effect on 
macrophage proliferation in lean mice (data not shown). These results suggest that 
macrophage proliferation is able to rapidly respond to environmental conditions in the 
adipose tissue.  
 
In summary, we show here that macrophage proliferation within adipose tissue is a 
dynamic mechanism that increases with weight gain and decreases with weight loss. 
Prolonged depletion of circulating monocytes in obese mice had no effect on adipose 
tissue macrophage content, while EdU exposure studies revealed that at least half of the 
adipose tissue macrophages proliferated within an 80 hour period in the visceral adipose 
tissue of obese mice. Overall, these results suggest that local proliferation, not 
recruitment of circulating monocytes, is the predominant process by which the large 
population of macrophages present in the obese adipose tissue is maintained in the steady 
state. These results also imply that local macrophage proliferation contributes to the 
massive accumulation of pro-inflammatory macrophages and the inflammation of 
adipose tissue in obesity.  
 
Current therapeutic strategies to decrease macrophage content in the obese adipose tissue 
to improve insulin sensitivity have focused on blocking the infiltration of monocytes into 
adipose tissue108,115,134,235. Our data now show that proliferation is an important process by 
which macrophages accumulate in adipose tissue in obesity, which could be considered 
in future therapeutic strategies. In this context, further investigation will be needed to 
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understand the mechanisms by which obesity stimulates macrophage proliferation 
specifically within adipose tissue and not other tissues.  
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Experimental Procedures 
 
Animals, Diets and Treatments 
8 to 12 week-old male wild-type C57BL/6J (WT) and B6.V-Lepob/J (ob/ob) mice were 
obtained from Jackson Laboratory (Bar Harbor, Maine, USA) and maintained on a 12-
hour light/dark cycle. Animals were given free access to food and water. C57BL/6J wild-
type mice were fed a high-fat diet (45% calories from lipids; D12451; Research Diets 
Inc., New Brunswick, New Jersey) for 7-14 weeks beginning at 8 weeks of age. All other 
mice were fed normal chow diet (Prolab 5P76 Isopro 3000, LabDiet,  St. Louis, Missouri, 
USA). Intraperitoneal GTTs were performed as previously described236. Animals were 
weighed, sacrificed by cervical dislocation, and adipose tissues (epididymal and inguinal 
depots), livers and spleen were harvested at age 7-14 weeks. For the in vivo EdU 
injection studies, 8-12 week-old mice were intraperitoneally injected with 1 mg EdU in 
200 µl phosphate-buffered saline (PBS) and three hours later mice were sacrificed by 
asphyxiation with carbon dioxide and immediately bled by cardiac puncture prior to 
tissue dissection. For the in vivo EdU drinking water studies mice were given free access 
to water containing 1 mg/ml EdU and 2% sucrose to offset taste aversion. For the CL-
316,243 studies, mice were intraperitoneally injected with 0.5 mg/kg CL-316,243 in PBS, 
and sacrificed 24 hours later. Tissues to be analyzed by flow cytometry were processed 
immediately; other samples were frozen in liquid nitrogen and stored at –80°C prior to 
RNA extraction or fixed in formaldehyde prior to immunohistochemical analysis. All 
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procedures were performed in accordance with protocols approved by the University of 
Massachusetts Medical School’s Institutional Animal Care and Use Committee. 
 
Liposome Preparation 
PBS and clodronate-loaded liposomes were made in a precisely scaled-down version of a 
method previously described237. Chloroform, phosphatidylcholine, cholesterol and 
clodronate were all purchased from Sigma. All chloroform solutions were made in glass 
vials and transferred with borosilicate pipettors. Solutions were filtered through 0.22 μm 
mixed cellulose ester filters (VWR) using a glass Hamilton syringe. 2.5 ml of 
phosphatidylcholine in chloroform (100 mg/ml) were added to 2.3 ml cholesterol solution 
(10 mg/ml in chloroform) in a 50 ml round-bottom flask. The chloroform was removed 
by low-vacuum rotary evaporation at 40°. After removal of chloroform, and the flask was 
aerated with sterile vent-filtered compressed air for up to 1 hour, until all traces of 
chloroform odor was removed. The phospholipid film was then dispersed in 12 ml PBS 
(for empty liposomes) or 0.7 M clodronate solution in PBS (for clodronate liposomes) by 
gentle rotation (max., 100 rpm) at room temperature (RT) for 20–30 min. The milky 
white suspension was kept at RT for 90 minutes and then sonicated in a waterbath for 
3 min. The suspension was then kept overnight at 4°C to allow swelling of the liposomes. 
Before use, the liposomes were washed to remove un-encapsulated clodronate by 
centrifugation at 22,000g and 10°C for 60 min, followed by four more washes at the same 
speed for 25 minutes. The final liposome pellet was resuspended in sterile PBS and 
  
72 
adjusted to a final volume of 12 ml. Before i.v. injection the liposomes were filtered 
through Swinnex filters (Millipore) with 3 μm pores. 
 
Isolation of macrophages from adipose tissue SVF. 
Adipose tissue SVF cells were prepared from collagenase-digested adipose tissue, as 
described previously236. Briefly, epididymal or inguinal fat pads were mechanically 
dissociated using the gentleMACS Dissociator (Miltenyi Biotec) and digested with 
collagenase at 37°C for 45 minutes in Hank’s buffered saline solution (HBSS) (Gibco, 
Life Technologies) containing 2% bovine serum albumin (American Bioanalytical) and 2 
mg/ml collagenase (collagenase from clostridium histolyticum, Sigma). Samples were 
then filtered through 100 µm BD falcon cell strainers and spun at 300 g for 10 minutes at 
room temperature. The adipocyte layer and the supernatant were aspirated and the 
pelleted cells were collected as the SVF. The cells were then treated with red blood cell 
(RBC) lysis buffer, washed in PBS and then stained for flow cytometry.  
 
Liver and spleen cell isolation 
Liver cells were isolated as previously described238. Briefly, the livers of freshly 
asphyxiated mice were perfused with collagenase 4 mg/ml in 1% BSA in HBSS via the 
inferior vena cava and/or portal vein until livers were blanched. Small incisions at the 
edges of the liver were made to assist in complete blanching. After several minutes of 
perfusion, livers were then placed in collagenase solution at 37°C with gentle rocking for 
20-30 minutes. The resulting cell digest was filtered through a 100 µm filter mesh and 
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several 30g centrifugation steps pelleted out hepatocytes. The remaining cells were 
pelleted by centrifugation at 500g and washed several times with HBSS. The cells were 
treated with RBC lysis buffer and then stained for flow cytometry. Spleens were 
manually dissociated using the plunger of a 1 ml plastic syringe in cold HBSS. The 
resultant cell suspension was centrifuged at 500g and the cell pellet was treated with RBC 
lysis buffer. A portion of the splenocytes were than taken for flow cytometry staining. 
 
Flow cytometry 
Cells were resuspended in PBS containing 1% BSA (FACS buffer) containing Fc block 
(clone 2.4G2, eBioscience, San Diego, California, USA) and allowed to block non-
specific binding for 15 minutes at 4°C. Cells were then counted and incubated for an 
additional 20 minutes in the dark at 4°C with fluorophore-conjugated primary antibodies 
or isotype control antibodies. Antibodies used in these studies included:  
F4/80-APC (clone Cl:A3-1, AbD Serotec, Raleigh, North Carolina, USA), CD11b-
PerCP-Cy5.5 (clone M1/70), Gr-1-APC-Cy7 (clone RB6-8C5), Siglec-f-PE (clone E50-
2440), Ly6C-PE-Cy7 (clone AL-21), Ki67-FITC (clone B56) and IgG1κ-FITC (clone 
MOPC-21, BD Pharmingen San Diego, California, USA), and CD11c-V450 (clone HL-3, 
BD Horizon, San Jose, California, USA). For the EdU experiments, cells were surface 
stained according to manufacturer’s instructions. Following incubation with primary 
antibodies, cells were washed and fixed with fixation/permeabilization buffer 
(eBioscience) and then permeabilized with permeabilization buffer (eBioscience). EdU 
was chemically conjugated to Alexa 405 or Alexa 647 fluorophore according to the 
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instructions of the manufacturer (Invitrogen). Sample data were acquired on a BD LSRII 
(BD Biosciences) and analyzed with FlowJo software (Tree Star). Sample data were 
initially gated on forward and side scatter, followed by a singlet cell gate, and then a gate 
to remove auto-fluorescent debris (see Figure S1 for complete gating scheme).  
 
Immunohistochemistry  
Adipose tissue SVF cells were plated overnight on glass coverslips in complete DMEM 
and then fixed for 15 min at room temperature in 4% paraformaldehyde. Cells were 
washed twice with PBS containing 0.3% Triton x-100 (American Bioanalytical, Natick, 
Massachusetts, USA) and blocked with 10% normal goat serum and were then incubated 
with the following antibodies: rat anti-mouse F4/80 (AbD serotec, Raleigh, North 
Carolina, USA; 1:50 dilution), and goat-anti-mouse Ki67 (Abcam, Cambridge, 
Massachusetts, USA; 1:200 dilution) overnight at 4°C. After washing, the cells were 
incubated with secondary antibodies (1:200 dilution) for 30 minutes at room temperature. 
Cells were mounted in ProLong Gold antifade reagent containing 4',6-diamidino-2-
phenylindole (DAPI)  (Molecular Probes, Eugene, Oregon, USA). Adipose tissue 
sections were blocked with 10% normal goat serum and were then incubated with anti-
BrdU or Ki67 antibodies and hematoxylin stained. Images were captured on a Zeiss 
Axiovert 200M microscope using Axiovision software (Carl Zeiss, Thornwood, New 
York, USA).  
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Statistical analysis 
All values are shown as means ± SEM. Student's t-test for two-tailed distributions with 
equal variances was used for comparison between two groups; for comparisons ≥ 3 
groups, two-way ANOVA was used followed by the Tukey post test. Differences p ≤ 
0.05 were considered significant. Data were entered into Microsoft Excel, and statistical 
analyses were performed with Graph Pad Prism 5.  
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Supplemental Figure 2.3. Adipose Tissue Macrophage Proliferation Occurs 
Independently of Blood Monocyte Recruitment. ob/ob mice were i.v. injected with 
either PBS-liposomes or clodronate-liposomes every 16 hours. 18 hours after initial 
injection, the mice were given drinking water containing EdU. (A) Macrophage content 
in the inguinal adipose tissue of PBS-liposome-treated, clodronate-liposome-treated, 
untreated ob/ob mice and untreated wild-type mice; n=5 mice per group. (B) 
Quantification of EdU incorporation into ATMs during 32h and 80h of exposure to EdU 
drinking water in PBS-liposome-treated and monocyte-depleted clodronate-liposome-
treated ob/ob mice; n=4-5 mice per group. (C) Percentage of macrophages that are 
CD11c+ in macrophages that incorporated EdU (EdU+) or not (EdU-) during an 80-hour 
EdU exposure in epididymal AT of ob/ob mice. n=9-10 mice/group. All graphs are 
expressed as mean ± s.e.m. Statistical significance was determined by Student’s t-test. ns 
= not significant.  
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Supplemental Figure 2.4. Effect of obesity on proliferation of diverse immune cell 
types within adipose tissue of ob/ob mice.  
(A) Representative dot plots of CD11b+ SVF cells stained for the eosinophil marker 
Siglec-f. (B) Percentages of CD11b+ cells that are eosinophils in WT and ob/ob mice. n= 
48-51 mice/group from 10 independent experiments. (C) Representative dot plot of SVF 
eosinophils 3 hours after EdU injection. (D) Representative dot plots of CD11b+ SVF 
cells stained with the neutrophil marker Gr-1. (E) Percentages of CD11b+ cells that are 
neutrophils. n= 14-15 mice/group from 3 independent experiments. (F) Representative 
dot plot of SVF neutrophils 3 hours after EdU injection. (G) Percentage of macrophages 
that are CD11c+ in WT and ob/ob SVF. (H) Percentages of CD11c+ and CD11c– 
macrophages that incorporated EdU during a 3-hour in vivo pulse or a 3-hour ex vivo 
pulse. n=14-15 mice/group from 3 independent experiments. All graphs are expressed as 
mean ± s.e.m. Statistical significance was determined by Student’s t-test. ns = not 
significant. **p<0.01; ***p<0.001. 
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Supplemental Figure 2.5 Adipose tissue macrophage proliferation decreases with 
weight loss in mice. Mice were fed a HFD or ND for 7-14 weeks. (A) Weights and (B) 
GTT of ND (●) and (■) HFD mice; n=5 mice/group. SVF cells from inguinal fat pads 
were isolated and analyzed by flow cytometry. (C) Representative flow cytometry dot 
plots of the SVF F4/80 and CD11b staining. (D) Percentage of macrophages in SVF for 
ND, HFD and fasted mice. (E) Representative flow cytometry dot plots of Ki67 staining 
in ATMs. (F) Percentage of macrophages positive for Ki67 in ND, HFD and fasted mice. 
All graphs are expressed as mean ± s.e.m. Statistical significance was determined by 
Student’s t-test. **p<0.01; ***p<0.001. 
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CHAPTER III: Discussion and Future Directions 
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Obesity and diabetes are major public health problems facing the world today. 
Extending our understanding of adipose tissue biology, and how it changes in obesity, 
will hopefully better equip our society in dealing with the obesity epidemic. Macrophages 
and other immune cells accumulate in the adipose tissue in obesity and secrete cytokines 
that can promote insulin resistance. ATMs are thought to originate from bone marrow-
derived monocytes, which infiltrate the tissue from the circulation. Much work has been 
done to demonstrate that inhibition of monocyte recruitment to the adipose tissue can 
ameliorate insulin resistance. While monocytes most certainly can enter the adipose 
tissue, we have shown here that local macrophage proliferation may be the predominant 
mechanism by which macrophages self-renew in the adipose tissue.  
Overall, the results presented above suggest that local proliferation unexpectedly 
makes a major contribution to maintaining the large population of macrophages present 
in the obese adipose tissue in the steady state. This suggests that increased rates of local 
macrophage proliferation may also be partly responsible for the massive increase in ATM 
content that occurs in obesity. This information could have implications for future 
therapeutic strategies in the management of diabetes.  
 
 These findings raise a plethora of questions relating to the mechanism and 
consequences of macrophage proliferation within the adipose tissue. What growth factor, 
cytokine, or other signal is responsible for promoting the dramatic increase in 
macrophage proliferation in the adipose tissue in obesity? What is the origin of that factor 
and why is its activity increased in obesity? What intracellular signaling pathways are 
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required for macrophage proliferation in adipose tissue? What is the relative contribution 
of local macrophage proliferation vs. monocyte recruitment in maintaining the total 
macrophage population in obese adipose tissue? What is the average macrophage 
residence time in the adipose tissue and does it change in obesity? How do macrophages 
leave the adipose tissue? What is the metabolic implication of increasing or inhibiting 
macrophage proliferation specifically in the adipose tissue? I will conclude this 
dissertation with a discussion of a few of these issues. 
 
What is the signal that is promoting local macrophage proliferation in adipose tissue? 
In Chapter One, I reviewed the majority of known examples of local macrophage 
proliferation in adult mammalian tissues that exist at this time. In the lung, skin, kidney 
and atherosclerotic plaques, various studies have identified the factors involved in 
promoting local macrophage proliferation. I will review them here and discuss their 
implications for adipose tissue macrophage research.  
In the lung, it appears that granulocyte-monocyte colony stimulating factor (GM-
CSF) is critical for normal alveolar macrophage function, as GM-CSF KO mice have 
pulmonary pathology239, and at least one study has linked that defect to the role of GM-
CSF in both alveolar macrophage function and stimulation of alveolar macrophage 
proliferation240. Macrophage colony stimulating factor (M-CSF) has also been found to be 
important in alveolar macrophage content in mice younger than than 3 week old, but not 
adult mice241. Also, as discussed previously, a recent study identified eosinophil-derived 
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IL-4 to be the sole factor responsible for driving local macrophage proliferation in the 
lung during helminth infection151.  
In the skin, one study showed that young mice lacking the receptor for M-CSF 
completely lack Langerhans cells154. They also showed that even during the repopulation 
phenomenon that occurs in damaged skin in wild-type mice, circulating monocytes enter 
the inflamed skin and undergo several rounds of proliferation, forming clusters of 
Langerhans cells154. This proliferation was also dependent on the M-CSF receptor on the 
incoming monocytes.  
In the kidney, M-CSF has been identified as the driving force in the stimulation of 
local proliferation in rat models of kidney injury242 and kidney M-CSF expression is 
elevated in human glomerulonephritis, in which areas of high M-CSF expression levels 
were co-localized with high rates of local macrophage proliferation243. Interestingly, 
macrophage proliferation in allograft transplant rejection models is also dependent on M-
CSF, and antibody-mediated blockade of the M-CSF receptor was found to significantly 
alleviate macrophage recruitment to allografted kidneys244. It is worth noting that 
inhibition of macrophage proliferation may be a promising therapeutic avenue to 
attenuate kidney injury in these conditions. 
 In atherosclerosis, numerous studies have identified oxidized LDL particles as 
one of the factors promoting macrophage proliferation in plaques245-248. Indeed, treatment 
of mice with cholesterol-lowering statin drugs has been shown to reduce macrophage 
content in atherosclerotic plaques249,250 and at least one study has shown that statins 
inhibit oxidized-LDL-induced macrophage proliferation by inhibiting the mitogen 
  
89 
activated protein kinase (MAPK) p38 in macrophages251. Several reports indicate that 
both M-CSF and GM-CSF are critical in the macrophage proliferative response to 
oxidized LDL245,247,252.  
These studies on macrophage proliferation in other tissues will hopefully inform 
future studies of macrophage proliferation in adipose tissue. For example, it is tempting 
to speculate that M-CSF, GM-CSF or some form of lipid are the factors promoting 
macrophage proliferation in adipose tissue as they are in atherosclerotic plaques. 
Unfortunately, very few studies on the role of M-CSF and GM-CSF exist in the adipose 
tissue at this time. Weisberg et al. reported that adipose tissue macrophage content was 
decreased in lean mice that were deficient in M-CSF, although these mice have severe 
skeletal abnormalities and lack teeth, and do not become obese even on a high fat diet11. 
Another study demonstrated that mice deficient in GM-CSF do become obese on a high 
fat diet but were more insulin sensitive, and have decreased macrophage content and 
inflammatory gene expression in their adipose tissue253. While this may have been the 
result of a defect in monocyte recruitment to the adipose tissue, it is possible that GM-
CSF deficiency led to an inhibition of local macrophage proliferation within the adipose 
tissue. For the sake of completeness, it is worth nothing that adipose-tissue and depot-
specific overexpression of M-CSF in rabbits was associated with a 16-fold increase in 
localized adipose tissue growth compared to controls despite no change in diet254 . The 
role of macrophages in stimulating the adipose tissue growth in this study is unclear, as 
macrophage content was not adequately documented254. 
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In our lab, gene chip and RT-PCR studies have shown no increase in M-CSF or 
GM-CSF in obese adipose tissue at the mRNA level. However, we plan to measure the 
protein levels of these growth factors in the adipose tissue or in lymph draining from the 
adipose tissue. Preliminary experiments with M-CSF and GM-CSF injections in lean 
mice have yielded promising results in increasing macrophage content in adipose tissue, 
and inhibition of GM-CSF with neutralizing antibodies in obese mice has also yielded 
promising initial results in inhibiting ATM proliferation (data not shown). There may 
also be a role for IL-4 in ATM proliferation, but the dramatic decrease in eosinophil 
content and IL-4 expression that occur in the adipose tissue in obesity (Supplementary 
Figure 2.4) make it unlikely that IL-4 is the endogenous signal promoting ATM 
proliferation.  
 
While we found that adipocyte release of free fatty acids through lipolysis 
actually decreased ATM proliferation in obese mice (Figure 2.5), investigation of other 
lipid signals may still represent a fruitful avenue of research in macrophage proliferation 
in adipose tissue. For example, in addition to oxidized LDL stimulation of macrophage 
proliferation in atherosclerosis, several other lipids have been shown to directly promote 
macrophage proliferation. One group has published several studies reporting that various 
lipids including cholesterol esters, triglycerides and several phospholipids, could 
accumulate in, and stimulate the proliferation of, murine peritoneal macrophage upon 
lipid treatment in vitro255-259. At least one additional lipid, ceramide 1-phosphate, has been 
shown to directly stimulate bone marrow-derived macrophage proliferation in vitro260. 
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Another study showed that conditioned media from adipocytes treated with conjugated 
linoleic acid has been shown to increase proliferation of a macrophage cell line in vitro261. 
Further studies will be required to determine if lipids released from adipocytes are 
responsible for stimulating ATM proliferation. Insight on this subject may also come 
from examining macrophage proliferation in a lipodystrophic mouse model with 
disrupted lipid metabolism, in which macrophage content and inflammatory gene 
expression in adipose tissue were found to be greatly increased, to levels even higher than 
those seen in obesity262. Alternatively, induction of adipocyte apoptosis causes release of 
triglyceride into the circulation, rather than fatty acids, and is associated with macrophage 
accumulation in adipose tissue263. Examining the proliferation of macrophages in these 
mice may also provide useful insight as to the signals promoting macrophage 
proliferation. Investigation of the above questions will hopefully also shed light on why 
obesity has a specific effect on macrophage proliferation in adipose tissue but not in other 
tissues. 
 
What intracellular signaling pathways are required for ATM proliferation? 
As reviewed above, macrophage-specific deletion of JNK was found to decrease 
macrophage content in adipose tissue80. While most of the other studies on myeloid-
specific gene knockouts employed lethal irradiation followed by bone marrow transplant, 
this study did not. Interestingly, the authors failed to demonstrate that the decrease in 
macrophage content was due to inhibition of monocyte recruitment to adipose tissue80. 
JNK activation has been shown in other studies to be critical for macrophage 
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development, proliferation and survival264. Indeed, the other MAP Kinases ERK and p38 
have already been shown to mediate proliferation in atherosclerotic plaque macrophages 
in vivo251,265. It may be very interesting to study the rates of adipose tissue macrophage 
proliferation in mice with macrophage-specific MAPK deletions.  
  
What are the relative contributions of local macrophage proliferation and monocyte 
recruitment to maintaining the total macrophage population in obese adipose tissue?  
 At least one study has directly demonstrated the recruitment of adoptively 
transferred labeled blood monocytes to the adipose tissue in obesity139. Similar 
experiments would need to be repeated and performed in conjunction with macrophage 
proliferation studies in order to answer these questions. For example, the work presented 
in Chapter 2 suggests that freshly recruited monocytes are not major contributors to the 
proliferating pool of macrophages in adipose tissue. However, prolonged EdU exposure 
with concurrent adoptive transfer of labeled monocytes may begin to shed light on the 
relative contributions of macrophage proliferation and monocyte recruitment in adipose 
tissue. In addition to these experiments, it would no doubt be very informative to adopt 
the approach taken in lungs, in which bone marrow transplant with upper body shielding 
revealed that, in the absence of lethal irradiation, alveolar macrophages persist for the 
lifetime of a mouse136. Therefore, experiments using bone marrow transplant of CD45.1 
or GFP+ donor marrow would reveal if and how quickly monocytes recruited from the 
blood replace resident tissue macs of host origin. Surgically joined parabiotic mice would 
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be another approach which would reveal the rate at which resident macrophages are 
replaced by circulating monocytes.  
 
What is the average macrophage residence time in the adipose tissue and does it change 
in obesity? How do macrophages leave the adipose tissue? 
 Mechanisms of macrophage efflux out of adipose tissue have remained 
mysterious. However, the results presented in Chapter 2 suggest that in obesity in mice, 
complete turnover of the entire ATM population occurs somewhere in the range of once 
every one to two weeks (see Figure 2.4). Thus, there is no doubt that macrophages are 
leaving the adipose tissue at an appreciable rate.  One way to investigate the question of 
macrophage turnover would be to use the Kaede mouse, in which cells can be photo-
labeled and subsequently tracked using intravital microscopy or other methods266. In these 
experiments, a piece of adipose tissue would be exposed to light, causing the generation 
of a green fluorophore in the affected cells, and the disappearance of these cells from the 
adipose tissue would be followed over time. While technically challenging, this method 
does not cause any change in the behavior of cells, which is a distinct advantage over 
chemical or particulate dyes such as PKH26266. While macrophage efflux may occur, it is 
also entirely possible that macrophages may leave the adipose tissue by undergoing 
necrosis or apoptosis locally within the adipose tissue. Indeed, this has been shown to be 
the case in atherosclerosis (Reviewed in Andres, 2012174). Macrophage apoptosis markers 
could easily be studied in adipose tissue macrophages using microscopy and flow 
cytometry.  
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What are the metabolic implications of increasing or inhibiting macrophage proliferation 
specifically in the adipose tissue? 
Unfortunately, there appears to be no tissue- and cell-type specific way of 
inhibiting macrophage proliferation exclusively in the adipose tissue at this time.  Unlike 
in liver, where zymosan has been shown to induce macrophage proliferation163, 
intraperitoneal injection of glucan particles carrying siRNA causes an inhibition of 
macrophage proliferation in adipose tissue (our data, not shown). In atherosclerosis, 
macrophage proliferation can be increased using myeloid-specific knockouts of tumor-
suppressor genes (Reviewed in Andres, 2012174). Similar experiments may provide 
insight into the metabolic consequences of increasing macrophage proliferation in 
adipose tissue as well.  
 
 
In conclusion, we have shown here that local macrophage proliferation may be 
the predominant mechanism by which macrophage density is maintained in the obese 
adipose tissue. Local macrophage proliferation may also be responsible for the increase 
in ATM content that occurs in obesity. Further investigation of this phenomenon, its 
metabolic consequences, and the other mechanisms regulating macrophage content in 
adipose tissue may one day contribute to improving human health.  
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